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ABSTRACT 
 
SARAH ANN KEIM: Long-chain Polyunsaturated Fatty Acids in Breast Milk and Infant 
Formula, Maternal Perinatal Mental Health, and Infant Development 
(Under the direction of Julie Daniels) 
 
This study examined the associations between maternal perinatal mental health or 
exposure to long-chain polyunsaturated fatty acids (LCPUFAs) in relation to infant 
development in the Pregnancy, Infection, and Nutrition Study (2002-2006) (n=358).  Certain 
LCPUFAs have been shown to benefit visual acuity, while maternal mental health may 
negatively affect child development.  Women completed questionnaires during pregnancy to 
assess trait anxiety and depressive symptoms.  A home visit in the fourth postpartum month 
assessed perceived stress and depressive symptoms, collected infant feeding data, and 
obtained breast milk samples.  Infant development was assessed at 12 months using the 
Mullen Scales of Early Learning.  Multivariable linear regression was used to examine the 
associations between trait anxiety, perceived stress, and depressive symptoms in relation to 
Mullen scores.  Similar techniques were used to examine LCPUFA exposure in relation to 
Mullen scores and whether women with elevated depressive symptoms had lower breast milk 
docosahexaenoic acid (DHA) concentration. 
High levels of trait anxiety were associated with lower Receptive Language (adjusted 
β=-2.9, 95% confidence interval: -5.6, -0.3) and Early Learning Composite (adjusted β =-4.5, 
CI: -8.9, 0.0) scores.  No associations were observed between anxiety and other sub-scale 
scores or between perceived stress or depressive symptoms and Mullen scores.  Mean DHA 
content of breast milk samples was 0.28% of fatty acids (standard deviation=0.22); mean
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arachidonic acid (AA) content 0.57% (SD=0.20).  Women with elevated depressive 
symptoms before 20 weeks gestation had 25% lower breast milk DHA than women with few 
symptoms.  Upon adjustment for preterm birth, smoking, race and ethnicity, and education, 
no differences in development were observed in relation to breastfeeding exclusivity.  No 
association was observed between the LCPUFA content of breast milk and formula and 
development. 
Maternal anxiety may influence overall infant cognitive development and the ability 
to process verbal input.  Women who experienced elevated depressive symptoms in early 
pregnancy may have less DHA available to their infants.  However, this study found no 
evidence of enhanced development related to LCPUFAs.  Given the conflicting results 
among previous studies and this study’s limitations, no actions are currently warranted to 
change infant feeding practices except to note that infant LCPUFA supplementation deserves 
further study. 
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CHAPTER 1 
INTRODUCTION 
Healthy neurodevelopment during gestation and infancy can provide a foundation for 
positive behavioral and cognitive outcomes later in childhood and beyond.  Infants who are 
born at term and at a healthy weight, unexposed to substances like tobacco and alcohol, to a 
mother with a healthy diet, and into a supportive home environment are likely to see these 
advantages reflected in their intelligence and behavior, school performance, and mental 
health later in life.1-6  Meanwhile, infants born without these advantages may not attain their 
full developmental potential.  Identifying and better understanding the factors that promote or 
impede healthy development during gestation and infancy can help inform obstetric and 
pediatric practice as well as public health policy to optimize outcomes. 
The particular role of certain dietary long-chain polyunsaturated fatty acids 
(LCPUFAs) in healthy brain development has been of interest for several decades.  Fatty 
acids are important constituents of cell membranes, and LCPUFAs accumulate in large 
concentration in the developing brain, particularly in the gray matter (especially the synaptic 
membranes) and in the rod photoreceptors of the retina.7-10  Docosahexaenoic acid (DHA) 
has been of primary interest for these reasons.  DHA and other LCPUFAs like arachidonic 
acid (AA) are present in human breast milk and are also added to enhance some 
commercially-available infant formula products.  A number of studies have found that DHA 
intake is associated with positive outcomes like improved visual acuity particularly in 
preterm infants, but other studies have found no association.11-15  A beneficial effect on  
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development has been suggested but remains uncertain as well.16-19  Lack of clear 
associations may be because of the variation in the type of formulas or supplements fed to 
participants or differences in the outcome measurements used; also, many previous studies 
have been hampered by sample size constraints, limited length of follow-up, or poor control 
of confounding.  Most studies in this area have been feeding or supplementation trials, which 
have the advantage of a randomized design but may have limited generalizability.  
Observational studies have been challenged by issues of confounding since choices about 
breastfeeding and formula feeding are intertwined with factors like socioeconomic status.  
Improved understanding of the role of LCPUFAs in development could help refine guidance 
about infant feeding practices and the content of infant formulas.  The present study will 
examine the association between feeding method, infant exposure to DHA and AA during the 
first 4 months of life and developmental outcomes at 12 months of age, using detailed 
information about feeding patterns and breast milk content and accounting for key 
confounders. 
Depression affects between 6 and 17 percent of women at some point during their 
lifetime.20-22  The life stages corresponding to pregnancy and new motherhood may be 
particularly susceptible periods; postpartum depression affects up to 19 percent of new 
mothers, and an estimated 12 to 18 percent of women are depressed during pregnancy.23, 24  
Anxiety, stress, and depressive symptoms are inter-related phenomena; women who perceive 
their circumstances as highly stressful are also likely to experience more depressive 
symptoms or anxiety.25  Numerous studies have observed an association between maternal 
postpartum or chronic depressive symptoms and poorer child performance on cognitive and 
behavioral assessments.26-35  Studies noted that greater maternal stress and anxiety interfere 
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with mother-child interaction, with consequences for infant temperament and cognition.36-39  
However, few studies have reported negative effects as early as infancy, and those results 
have been inconsistent.29, 40, 41   
Additionally, depressed adults have been shown to have lower circulating levels of 
DHA, and depressed women may have inadequate supplies of fatty acids to pass 
transplacentally to their fetus or to feed them via breast milk.42-44  The present study will 
explore the association between maternal depressive symptoms, trait anxiety, and perceived 
stress during pregnancy and postpartum and infant developmental outcomes at 12 months of 
age.  Whether women with elevated depressive symptoms have lower concentrations of DHA 
in their breastmilk will also be examined. 
The present study is an opportunity to address questions about the role of LCPUFA 
exposure and maternal psychological health in infant development.  Women and their 
children (n=358 children) who were followed prospectively from early pregnancy to one year 
of age and completed assessments of maternal depressive symptoms, trait anxiety, and 
perceived stress; infant development; and infant feeding practices will be included in the 
present study.  The study has several advantages over previous research.  First, no other 
observational studies of infant development have incorporated detailed information about the 
fatty acid content of both breast milk and infant formula (both formulas with LCPUFAs 
added and those without LCPUFAs).  Second, few studies assess women for depressive 
symptoms during pregnancy and postpartum, and this study assessed depressive symptoms at 
three time points.  Third, this study uses the Mullen, an assessment of multiple 
developmental domains.  Fourth, the study population for this study more closely resembles 
the general population of women and infants than some studies which drew samples of 
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women who were clinically depressed.  Finally, the study incorporates data on the potential 
confounders that often plague research on breastfeeding or LCPUFA exposure and brain 
development.  As a result, the present study can help address some of the shortcomings of 
previous studies and build upon the present understanding of the role of LCPUFAs and 
maternal psychological health in early child development.  The study is based on prospective 
data from the Pregnancy, Infection, and Nutrition (PIN) Study of pregnant women in central 
North Carolina and its postpartum component involving their infants.45 
CHAPTER 2 
REVIEW OF THE LITERATURE 
Introduction 
For several decades intense research efforts have been placed on uncovering the 
factors that underlie healthy development of the human brain during gestation and infancy.  
Likewise substantial effort has gone toward identifying exposures that are harmful to 
neurodevelopment with the goal of eliminating those exposures.  It is clear that children who 
experience a healthy start to life and live in a nurturing early environment are more likely to 
achieve educationally, be productive adults, bear healthy children themselves, and live free 
of mental illness.   
This healthy start may begin even before conception with the health of the parents, 
but it certainly can be marked with the earliest signs of fetal brain development.  The first 
few weeks of gestation are marked by the development of the notochord and the neural tube.  
Cell proliferation, neuronal migration and synaptic formation begin to at least some extent 
during the first trimester, and the total complement of adult neurons is present in the fetal 
brain by the time the brain growth spurt starts in the third trimester.46-48  From the third 
trimester of in utero development to approximately 18 months of age, the brain undergoes 
dramatic growth in terms of overall size and cell number.49  Myelination occurs as well as a 
large increase in dendritic complexity and synapse formation.47, 48  At the time of birth, the 
human brain has already attained 27 percent of its final adult weight.46  The brain growth 
spurt has been identified as a critical window where a wide range of exposures have been
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shown to be harmful to the developing brain.  For instance, during the third trimester, fetal 
exposure to alcohol has been associated with cerebral growth restriction and neuronal loss 
and exposure to lead with reduced intelligence.5, 50  From a psychosocial perspective, it is 
apparent from studies like the Infant Health and Development Program that positive 
influences like presence of caregivers and interventions like home visiting during infancy 
result in better cognitive and behavioral outcomes.2, 51 
 
Long-chain polyunsaturated fatty acids and infant development  
Background and Significance 
Various aspects of diet play important roles in brain development, both during 
pregnancy and in infancy.  Appropriate maternal weight gain during pregnancy has been 
shown to be important for fetal growth which is directly related to brain development.52  Iron 
deficiency during pregnancy and in childhood has been shown to adversely effect behavior in 
childhood.53-55  And, inadequate supplies of choline and folate during fetal development can 
result in neural tube defects.56, 57  Iodine seems important for cognition and motor 
development in childhood.58  Over the past two decades much research has focused on the 
role of dietary omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids in infant 
neurodevelopment.  Some members of these classes of fatty acids can be produced 
endogenously, but dietary sources are essential for certain fatty acids.  Linoleic acid (LA) and 
α-linoleic acid (ALA) are the predominant forms present in the human diet and are 
considered essential fatty acids since they cannot be produced endogenously.49  Most fatty 
acid metabolism is performed by the liver where fatty acids are elongated and desaturated to 
other forms, including DHA (22:6n-3) and AA (20:4n-6).49  DHA and AA are members of a 
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group of fatty acids known as LCPUFAs because of their structure consisting of more than 
18 carbon atoms.49, 59  DHA and AA are themselves present in a range of food sources as 
well as produced endogenously from ALA and LA.49  DHA is found in abundance in seafood 
like atlantic salmon, pacific cod, and tuna and also in certain oils and nuts; AA is found 
particularly in egg yolks and animal fats and organ meats.60, 61  Human breast milk also 
contains DHA and AA, and many infant formulas are enhanced with DHA and AA.62-65  
In the human body, LCPUFAs play a number of roles including as components of 
membrane phospholipids and as precursors of prostaglandins, thromboxanes, and 
leukotrienes.59, 66, 67  AA can be found in most tissues in the human body, while DHA tends 
to be more highly concentrated in the brain, retina, and testis.49  Within the retina and brain 
tissues, DHA concentrates in the rod photoreceptors and synaptic membranes in the gray 
matter.8, 9, 68  During the brain growth spurt, the amount of DHA in the brain increases 
substantially in both an absolute and relative sense.49  Between 25 weeks gestation and 2 
years of age, the total amount of DHA in the brain increases from 3,000 nmol per gram brain 
to 10,000 nmol per gram brain.69  Also during the third trimester the liver and adipose tissues 
of the developing fetus build up stores of DHA to fuel postnatal neurodevelopment.70  During 
pregnancy, maternal DHA from the diet or endogenous production crosses the placenta and is 
the major contributor to the DHA in the fetal brain (Figure 2.1).49 
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Figure 2.1. DHA accretion in the fetal and infant brain (Adapted from Lauritzen 49) 
 
 
 
During gestation the fetal liver and adipose tissues store DHA, to provide a postnatal 
source for ongoing brain development.70, 71  Thus, the main reason why infants born preterm 
might require more dietary DHA than term infants is because they have lower internal stores 
to draw from.49  Lauritzen et al. estimates the difference in the DHA stores of an infant born 
at 30 weeks versus a term infant to be 4.5 g DHA.49  Clandinin et al. estimated that term 
infants have approximately 3.6 grams of total fatty acids in total brain tissue at birth, while 
preterm infants have an average of 1.1 grams.70  Both preterm and term infants can transform 
LA to AA and ALA to DHA.72  However, rates of transformation vary across individual 
infants and preterm infants may be unable to acquire or produce enough DHA and AA during 
infancy to make up for their deficit.73, 74 
Several factors affect the amount of LCPUFAs that the developing fetus obtains via 
the placenta or breast milk, and this may affect the amount of LCPUFAs available to the 
Maternal diet 
Absorption to maternal circulation 
Elongation and desaturation in maternal liver 
Maternal circulation Placental transfer 
Secretion in milk 
Fetal circulation 
Absorption to infant circulation 
Elongation and remodeling in liver 
Fetal blood brain barrier 
Incorporation into synaptic membranes and rod outer disk membranes 
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developing brain.  First, the third trimester of pregnancy generally corresponds to a natural 
increase in the amount of circulating fatty acids so more DHA is available during the period 
of rapid brain development.  Second, birth order plays a role.  Maternal stores of DHA are 
not completely replenished between pregnancies, so later children may receive less DHA 
than first births.75  While internal stores of DHA can help fuel postnatal brain development, 
dietary sources of DHA are likely the larger source for the infant.73  Human breast milk 
contains DHA in varying amounts depending on maternal diet, smoking, body mass index 
(BMI) and weight gain, parity, duration of lactation, adipose stores, and hepatic metabolism 
of fatty acids.  AA levels tend to be more consistent than DHA levels.73  Estimates of DHA 
concentration in the breast milk of women from the U.S. range from 0.06 to 0.29 percent of 
total fatty acids (FA%), and are lower on average than for other populations with high 
seafood intake.62, 63  For instance, Idota et al. estimated the DHA concentration in breast milk 
from a sample of Japanese women to be 1.00 FA%, and Jørgensen et al. found the 
concentration to be 0.43 wt% for a sample of Danish women.76, 77  Vegetarian and vegan 
women have lower levels of DHA in their breast milk than women who consume animal 
products; Sanders and Reddy estimated DHA in their sample to be 0.14 FA%.78  Breast milk 
fatty acid concentrations can fluctuate slightly day-to-day, but it has been estimated that 
preterm infants ingest approximately 24 mg DHA and 36 mg AA each day, while a 4-month 
old infant takes in 100 mg.49, 70  Jørgensen et al. estimate that fish intake could explain 55 
percent of the variability in breast milk DHA content.79  The LCPUFA concentration of 
breast milk does not seem to vary significantly across lactation, however.  Studies by 
Mitoulas et al. and Ribeiro et al. collected frequent samples over at least the first 4 months 
postpartum and observed no significant changes in DHA or AA content over time.80, 81  This 
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is in contrast to a few older studies that suggested a possible decrease over time, but these 
studies relied on samples collected at fewer time points.82, 83  Among women who smoke 
during lactation, breast milk LCPUFA levels tend to be lower than for non-smoking 
women.84  Maternal BMI and weight gain during pregnancy are also positively associated 
with the concentration of fatty acids in breast milk.85, 86  Maternal hepatic activity also 
contributes to breast milk fatty acid concentration, since the amount in breast milk exceeds 
the amount found in adipose stores and diet combined.49 
Infant formula manufacturers have strived to produce formulas as similar as possible 
to breast milk in how infants digest them and in their composition.87  Current 
recommendations for the content of essential fatty acids for infant formulas vary.  The U.S. 
Food and Drug Administration (FDA) issued nutrient requirements in 1985 including a 
requirement for at least 2.7 percent of total fatty acids to be from LA.88  The FDA convened 
an expert panel via the Life Sciences Research Office that provided recommendations for at 
least 8 percent of total fatty acids from LA, 1.75 percent from ALA, and a LA to ALA ratio 
of greater than 6 but less than 16.89  The 1991 report from the European Society for 
Paediatric Gastroenterology and Nutrition contained recommendations for formula LA 
content of 4.5 percent up to 10.8 percent.90  There is no consensus about the necessity of 
adding LCPUFAs to formula products.  However, a workshop involving many of the leading 
investigators in this field recommended that formulas for preterm infants contain 0.35 FA% 
as DHA and 0.4 FA% as AA, 0.2 FA% as DHA and 0.35 FA% as AA for term infants.91  In 
2002, the first infant formula product with DHA and AA added became available to 
consumers in the U.S.92  Formulas with LCPUFAs added had been available in Europe and 
some Asian countries since at least the early 1990s.93  The multiple studies carried out in the 
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1990s that suggested neurodevelopmental benefits of LCPUFAs were influential in 
manufacturers’ decisions to add DHA and AA to many of their products.  Most of the new 
formulas were based on existing products but with DHA and AA added, and in most cases 
both versions co-existed on the market for several years.  By 2007, many infant formulas 
were available in the enhanced version only.  The amount of DHA and AA added varies 
slightly by manufacturer (Appendix 1). 
Until formulas were modified to contain DHA and AA, formula-fed infants obtained 
DHA and AA by metabolizing LA and ALA.94  Studies based on postmortem examinations 
of formula or breastfed infants found that breastfed infants had a higher proportion of 
cerebral cortex fatty acids as DHA than infants fed formula with no added DHA and AA.94  
Also, the concentration of DHA in the brain increased across infancy for the breastfed infants 
but was constant for infants fed traditional formulas, suggesting that without a dietary source 
of DHA, the infant is not able to meet the needs of its rapidly developing brain.94  However, 
DHA concentrations in the infant retina did not vary between the groups nor did AA 
concentrations in the brain and retina.94.  The similarity in AA concentrations may be due to 
the composition of the formulas used at the time, where the specific LA and ALA levels 
resulted in metabolism of AA at levels close to those observed in breastfed infants.94  The 
results pertaining to concentrations in the retina may be because the amount of DHA in the 
retina plateaus at 40 weeks gestation, and the retina has mechanisms to conserve DHA in 
times of undersupply.94  A study by Farquharson et al. found that formula fed infants 
experienced a more rapid decrease in the concentration of DHA in liver and adipose tissue 
over the first ten postnatal weeks as compared to breastfed infants, indicating that formula 
fed infants tended to draw down DHA stores in the absence of dietary DHA.95, 96  Despite the 
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noted differences in LCPUFA concentrations in various infant tissues when comparing 
breastfed to formula fed infants, there remains uncertainty about whether differences in daily 
functioning (e.g., cognition, motor skills) result. 
 
Critical Review of the Literature 
Numerous studies have examined associations between various aspects of 
breastfeeding or LCPUFA supplementation and visual development, cognition and behavior 
ever since the first report by Hoefer and Hardy in 1929.97  Much of the evidence for a 
beneficial effect on neurodevelopment comes from studies comparing preterm infants fed 
formulas containing LCPUFAs to infants fed a control formula or breastfed.11, 12, 98  Many of 
these studies found a positive association between LCPUFA formulas or breast milk and 
plasma phospholipid or red blood cell DHA content and performance on tests of visual 
acuity.  Faldella et al. compared infants who received a formula with LCPUFAs to infants 
who received a traditional formula for preterm infants and infants who were breastfed.98  
They found that infants received the traditional formula lagged in the development of visual 
evoked potentials (VEPs), a measure of optic and brain visual processing maturation.98  A 
study by Uauy et al. measured electroretinographic (ERG) responses in very low birthweight 
infants to assess retinal maturity.  The infants were assigned to either human milk, formula 
low in n-3 fatty acids, formula with ALA, or formula with ALA and marine oils.99  They 
found that rod function was similar for the infants who received the formula containing DHA 
from marine oils or the human milk, and the other infants showed less well-developed 
function.99  Extending upon that work, the same team reported that VEP and forced-choice 
preferential looking at 36 and 57 weeks post-conception reflected comparable visual acuity 
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development between infants fed human milk and infants fed formula containing marine 
oils.11  Infants fed a traditional LA-containing formula performed the worst, while infants on 
a formula with ALA and LA performed in the intermediate range.11  In similar work led by 
Carlson, 33 preterm infants fed a marine-oil supplemented formula containing 
eicosapentaenoic acid (EPA), a LCPUFA, demonstrated better visual acuity as measured by 
the Teller Acuity Card test up until at least 6 months of age as compared to 34 infants on a 
traditional formula.12  However, no statistically significant differences were detected at 
subsequent ages.12  Also, it was found that the marine oil formula impeded infant growth and 
AA status, possibly due to the presence of EPA.74, 100  The DHA-formula fed infants had 
better visual acuity at term and 2 months (but not beyond 4 months) as measured by the 
Teller Acuity Card test.13  All of these studies were limited in size to approximately 10 to 35 
infants per experimental group, but all found some positive effects of DHA supplementation 
on visual development of preterm infants, even if the effect was transient. 
A number of other studies found no difference between supplemented and 
unsupplemented infants.  These include a study by Innis et al. that employed Teller cards at 2 
and 4 months.14  A study by O’Connor et al. found no effect on acuity using Teller cards at 2, 
4 and 6 months, but did see an advantage using swept-parameter VEP at 6 months.15   
A common finding for some of these studies is that effects seen at very young ages 
are no longer seen beyond 4 months of age.12, 13  It seems that LCPUFAs may accelerate very 
early visual development but unexposed infants eventually catch up.  One outstanding 
question is whether this short-lived advantage in visual acuity results in any longer-term 
advantage in terms of cognition and other aspects of development that matter for daily 
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functioning.  Further studies have attempted to answer this question by following children 
into later infancy and assessing global development. 
Tables 2.1-2.3 include studies from developed countries that assessed cognition 
(including language development), visual development (except acuity) or motor skills in 
children 18 months of age or younger.  This includes randomized and observational studies 
involving infants born at term or preterm. 
Researchers have taken several approaches to addressing the question of whether 
infants benefit from either breastfeeding or LCPUFA supplementation in terms of 
development of cognitive, visual or motor skills.  A number of studies have employed 
randomized designs while others have been observational.  Based on early indications that 
preterm infants might benefit more than term infants from breastfeeding or LCPUFA 
supplementation, some studies have continued to study preterm infants.  Others have 
attempted to detect effects in term infants.  Meanwhile, a small number of studies have tested 
supplements in pregnant or lactating women and looked for effects in their breastfed 
children. 
 
1. Randomized studies 
The results of randomized studies have been mixed.  A Cochrane review on this topic 
concluded that “there is little evidence from randomized trials of LCPUFA supplementation 
to support the hypothesis that LCPUFA supplementation confers a benefit for…general 
development of term infants….A beneficial effect on information processing is possible but 
larger studies over longer periods are required to conclude that LCPUFA supplementation 
provides a benefit when compared with standard formula.”101  These studies randomized 
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formula fed infants to one of one or more LCPUFA formulas or a control formula.  Most 
studies also included a breastfed comparison group (non-randomized).  Studies (n=20) that 
assessed infant development at 18 months of age or younger are listed in Table 2.1, Of the 
studies reviewed, 15 studies chose the Bayley Scales of Infant Development, 3 the Fagan 
Test of Infant Intelligence, 3 the MacArthur Communicative Development Inventories, 2 the 
Brunet-Lezine test, 1 the Infant Planning Test, 2 the Knobloch, Passamanick, and Sherrards 
test, 1 used gross motor milestones, and 1 an assessment of general movements.  Of the 
largest studies, only a few found that infants fed LCPUFA formulas performed significantly 
better than infants fed control formulas on the tests used.  A few of the small trials found a 
benefit of LCPUFA supplementation, but results remained inconsistent.  Studies that 
involved only preterm infants were more likely to show a benefit from LCPUFA 
supplementation than studies of term infants. 
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Table 2.1. Previous studies of LCPUFA supplementation and infant development 
Author (year) Study design 
(trial, 
observational) 
n 
Exposure Outcome 
measure(s) (age 
in months) 
Results 
Agostoni (1995)16 Trial, n=90 LCPUFA formula, 
control formula, 
breastfed 
Brunet-Lezine (4m) LCPUFA group scored higher than control formula group (105.3 
vs 96.5).  Breastfed group scored higher than control group (102.2 
vs 96.5).  F=4.93, p=0.009. 
Agostoni (2000)102 Trial, n=90 LCPUFA formula, 
control formula, 
breastfed 
Brunet-Lezine (4m, 
12m) 
Breastfed (25.4) and LCPUFA (26.0) groups scored higher on eye-
hand coordination than control formula group (22.0), p<0.001.  No 
differences on other scales or at 12 months 
 
Agostoni (2009)103 Trial, n=1160 20 mg DHA 
supplement or 
placebo 
Time to achievement 
of 4 gross motor 
milestones 
Sitting without support achieved sooner among supplemented 
group (26 weeks vs 27 weeks, p<0.001) 
Auestad (2001)104 Trial, n=404 LCPUFA formulas, 
control formula, 
breastfed 
Fagan (6m, 9m), 
Bayley (6m, 12m), 
MacArthur (9m, 
14m) 
Fagan – no difference in novelty preference, look duration 
between control and LCPUFA groups at 6 and 9 mos.  Bayley – 
no difference between groups at 6 and 12 mos.  MacArthur – no 
differences except mean vocabulary expression score higher for 
fish-LCPUFA formula than egg-LCPUFA formula (104±13 vs 
96±18) at 14 mos. 
Ben (2004)105 Trial, n=271 LCPUFA formula, 
control formula, 
breastfed 
Bayley (3m, 6m) LCPUFA group scored 2.4 pts higher on MDI, 3.6 pts higher on 
PDI compared to control formula group at 3 months.  No other 
differences observed. 
Birch (2000)17 Trial, n=56 DHA, DHA+AA, 
control formula 
Bayley (18m) DHA+AA group had higher MDI than DHA group (105.6 vs 
102.4) or control group (98.3) F=3.18, p<0.05.  No difference seen 
for PDI (101.7, 99.4, 98.6, H=4.05, p=0.13). 
Bouwstra (2003, 
2005)106-108 
Trial, n=397 LCPUFA formula, 
control formula, 
breastfed 
General movements 
(GM) (3m), Bayley 
(18m) 
Breastfeeding for >6 wks associated with less mildly abnormal 
GM (p<0.0015) and more normal-optimal GM (p,0.0025). Control 
infants had mildly abnormal movements more often than breastfed 
or LCPUFA groups (31 vs 19 vs 20%).  Bayley – no significant 
differences between control, LCPUFA, and breastfed groups 
(mean MDI=105.4±15.0, 102.7±15.4, 107.5±16.0; 
PDI=100.9±13.6, 99.4±13.4, 103.2±14.5) 
Carlson (1993)109 Trial, n=56  LCPUFA formula, 
control formula 
Bayley (12m) LCPUFA group scored lower on PDI (82.2 vs 92.6) than control 
group (p<0.03) 
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Clandinin (2005)110 Trial, n=361 LCPUFA formula 
(DHA, AA), 
LCPUFA formula 
(plus EPA), control 
formula 
Bayley (18m) LCPUFA groups 6-10 points higher on MDI (p≈0.05) 6 points on 
PDI than controls (p<0.05) 
Fang (2005)111 Trial, n=27 LCPUFA formula, 
control formula 
Bayley (6m, 12m) LCPUFA group scored higher on MDI (mean=96.1±8.6) then 
control group (91.7±10.4) at 6 mos. And at 12 mos (98.7±80, 
90.5±6.9).  For PDI at 6 mos (102.2±10.5, 95.4±13.2) and 12 mos 
(98.0±5.8, 86.7±11.1). Repeated measures ANOVA for MDI 
p=0.02, PDI p=0.008. 
Fewtrell (2002)112 Trial, n=240 LCPUFA formula, 
control formula, 
breastfed 
Knobloch (9m), 
Bayley (18m) 
No difference between LCPUFA and control groups on Knobloch 
(1.5 pts higher for LCPUFA group, CI: -1.8-4.7) or Bayley MDI 
(control group 2.6 pts lower, CI: -7.39-2.28) or PDI (2.1 pts, CI: -
6.8-2.67).  Breastfed group performed better on Knobloch than 
formula groups (5.7 to 7.2 pts higher, p<0.005) and on Bayley 
MDI (8.9 to 11.5 pts, p<0.005) and PDI (4.6-6.6 pts, p<0.005) 
Fewtrell (2004)113 Trial, n=238 LCPUFA formula, 
control formula 
Bayley (18m) No difference between LCPUFA and control group on Bayley 
except for boys on MDI (control group 5.7 pts lower, CI: 0.3-11.1) 
Lucas (1999)18 Trial, n=241 to 
250 
LCPUFA formula, 
control formula 
Bayley (18m), 
Knobloch (9m) 
Bayley – no difference between LCPUFA group and control group 
(difference in MDI=0.5, CI: -2.7-3.8; PDI=0.6, CI: -1.8-3.0). 
Knobloch – no difference overall (difference=0.5, CI: -1.6-2.7) or 
on subscales 
Makrides (2000)19 Trial, n=68 DHA, DHA+AA, 
control formula, 
breastfed 
Bayley (12m) No differences between breastfed (mean MDI=114+-13, mean 
PDI=101+-21) and DHA+AA group (MDI=108+-16, PDI=103+-
22) or any other group 
Makrides (2009)114 Trial, n=657 High DHA 
formula, standard 
DHA formula 
Bayley (18m) No difference in MDI scores except for girls (high DHA MDI 4.5 
pts higher (CI: 0.5-8.5) than standard DHA group) 
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O’Connor (2001, 
2003)15, 115 
2001 – trial, 
2003 - cohort 
from RCT, 
n=470 
2001 – LCPUFA 
fish oil formula, 
LCPUFA egg 
formula, breast 
milk, control 
formula. 2003 - 
predominantly 
breast milk, ≥50%, 
<50%, 
predominantly 
formula fed 
2001 - Fagan (6m, 
9m), Bayley (12m), 
MacArthur (9m, 
14m); 2003 -  Bayley 
(12m) 
Fagan – LCPUFA egg group scored higher (59.4±7.7) than 
LCPUFA fish group (57.0±7.5) and control group (57.5±7.4) on 
novelty preference (6), no difference at 9 mos. Bayley - No 
difference between groups in trial. Increasing breastfeeding 
duration associated with higher MDI at 12 mos.  MacArthur – no 
differences at 9 mos. in the trial, LCPUFA infants had better 
Vocabulary Comprehension than control infants (14) and 
increasing duration associated with higher Vocabulary 
Comphrension (9) 
Scott (1998)116 Trial, n=197 DHA formula, 
DHA+AA formula, 
control formula, 
breastfed 
Bayley (12m), 
MacArthur (14m) 
Bayley – no difference, Vocabulary Comprehension lower in 
DHA group than breastfed (92 vs 101, p=0.017), Vocabulary 
Production lower in DHA group than control formula group (91 vs 
101, p=0.052), no differences between DHA+AA group and 
breastfed group 
Van Wezel-Meijler 
(2002)117 
Trial, n=42 LCPUFA formula, 
control formula 
Bayley (3m, 6m, 
12m) 
No difference in Bayley MDI or PDI at any time point 
Werkman (1996), 
Carlson (1996)118, 
119
 
Trial, n=51-67 DHA formula, 
control formula 
Fagan (6.5m, 9m, 
12m) 
No difference in novelty preference but greater number of looks 
and shorter duration in DHA infants 
Willats (1998)120 Trial, n=44 LCPUFA formula, 
control formula 
Infant Planning Test 
(10m) 
LCPUFA infants had more intentional solutions (median=2.0 vs 
0.0, p=0.02) and higher intention scores (14.4 vs 11.5, p=0.04) 
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2. Observational studies 
Twenty-one observational studies are detailed in Table 2.2.  These studies varied 
widely in how they defined their exposure groups.  Some compared a breastfed group to 
formula fed groups, while others made comparisons among breastfed infants only.  Outcome 
measures likewise varied widely; 15 studies used the Bayley, 1 used the Denver 
Developmental Screening Test, 1 the Fagan, 1 used the Knobloch, 1 used the Alberta Infant 
Motor Scale, 1 used a measure of parent concern about the developmental progress of their 
child, 1 used a neurobehavioral score, and 1 used a customized measure of gross and fine 
motor skills and language.  Because of the varying definitions of the exposure groups and 
choice of outcome measures, it is difficult to compare results across studies.  The largest of 
these studies found that the odds of gross motor delay decreased with increasing duration of 
breastfeeding in a representative sample of infants from the United Kingdom, after adjusting 
for maternal age, birth weight, gestational age, maternal smoking, social class, maternal 
education, maternal employment, single parenthood, Malaise Inventory, postnatal 
attachment, parenting views, number of siblings, child care, and hours cared for by others 121.  
Many of the other studies found some benefit to longer breastfeeding.  However, the studies 
varied widely in the ability to control for important confounders, and the results are 
inconsistent.
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Table 2.2. Previous studies of breastfeeding and infant development 
Author 
(year) 
Study design 
(trial, 
observational) n 
Exposure Outcome 
measure(s)  
(age in months) 
Results 
Agostoni 
(2001)122 
Obs, n=44 Breastfeeding duration Bayley (12m) No significant differences between groups.  Group breastfed ≥ 
6 mos scored higher on PDI (difference=6.6, CI:-0.6-13.8) 
and MDI (2.0, CI: -3.2-7.3) than group breastfed < 6 mos 
Angelsen 
(2001)123 
Obs, n=345 Breastfed <3 mos., 3-6 
mos., ≥ 6 mos. 
Bayley (13m) Infants breastfed ≥ 6 mos had higher MDI than infants < 3 
mos (mean MDI=117.7(SD 11.7) vs 109.9 (13.1)).  No other 
differences among groups. 
Dee (2007)124 Obs cross-
sectional, 
n=22,399 
Breastfeeding initiation, 
duration 
Parent concern about 
language and motor 
skills 
Concerns about development inversely related to 
breastfeeding initiation, duration for those breastfed 3 or more 
months 
Bier (2002)125 Obs, n=39 Partially breast milk, 
formula fed 
Alberta Infant Motor 
Scale (3m, 7m, 12m), 
Bayley (7m, 12m) 
AIMS – milk group scored higher than formula group (adj 
mean=48 (SD=20) vs 35 (12), p=0.05) at 3 mos and 12 mos 
(62 (20) vs 47 (15) p<0.05) but not 7 mos.  Bayley – milk 
group scored higher on MDI (mean=100 (12)) than formula 
group (91 (10)) at 12 mos, but no difference at 7 mos. 
Florey 
(1995)126 
Obs, n=592 Breastfed, formula fed Bayley (18m) Breastfed infants scored 3.7 to 5.7 points higher on MDI than 
formula fed infants.  No differences for PDI. 
Gomez-
Sanchiz 
(2003)127 
Obs, n=249 Breastfed partially or 
exclusively > 4 mos., ≤ 
4mos., formula fed 
Bayley (18m) Group breastfed ≤ 4 mos group scored higher than formula 
group on MDI but not PDI (MDI β=4.7 CI: 1.7-7.7, PDI 
β=3.6, CI: -0.2-7.3). Group breastfed > 4 mos scored higher 
than group breastfed ≤ 4 mos. on MDI but not PDI (MDI 
β=7.2 CI: 4.3-10.1, PDI β=0.8, CI: -2.7-4.4). 
Innis (1996)128 Obs, n=433 Breastfeeding duration, 
exclusivity 
Fagan (10m) No difference in novelty preference found by duration or 
exclusivity. 
Eidelman 
(2004), 
Feldman 
(2003)129, 130 
Obs, n=86 >75%, 25-75%, <25% 
breast milk 
Bayley (6m) MDI and PDI scores were highest for >75% group 
(MDI=94.2±8.8, PDI=85.8±11.5) compared to 25-75% group 
(91.7±7.2 p<0.05, 78.6±12.6 p<0.01). No difference between 
25-75% group and <25% group  
Jacobson 
(2008)131 
Obs, n=109 Maternal plasma 
phospholipid levels * 
weeks exclusive 
breastfeeding 
Bayley (11m) No association between exposure and Bayley MDI or PDI  
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Lucas 
(1994)132 
Trial, n=114 Donor breast milk, 
formula fed 
Bayley (18m) Breast milk group scored lower than formula group on MDI 
(0.5 pts, CI: -6.2-7.1) and PDI (1.2 pts, CI: -4.4-6.8) 
Lucas 
(1989)133 
Trial, n=502 Donor breast milk, 
formula fed 
Knobloch (9m) Formula group scored higher on Knobloch than donor breast 
milk group (3.0 pts, CI: 0.5-5.6). 
Morley 
(1988)134 
Obs, n=771 Breastfed, formula fed Bayley (18m) Breast milk group scored higher on MDI (7.9 pts, p<0.01) and 
PDI (6.8 pts, p>0.001). 
Pinelli 
(2003)135 
Cohort from 
RCT, n=148 
Exclusively breastfed, 
partially breastfed, 
formula fed 
Bayley (6m, 12m) Infants >80% breastfed scored 1 points higher on MDI and 
PDI at 6 mos. and 1 point higher on PDI and MDI at 12 mos. 
(all p<0.05) 
Rogan 
(1993)136 
Obs, n=855 Breastfed ≥ 20 wks + 
weaned ≥ 50 wks, 5-19 or 
20 wks + weaned 19-49 
wks, ≤ 4 or 5-19 wks + 
weaned 9-19 wks, ≤ 4 
wks + weaned ≤ 9 wks, 
formula fed 
Bayley (6, 12, 18) No significant differences at 6, 12, 18 mos 
Sacker 
(2006)121 
Obs, n=14,660 Breastfeeding duration, 
exclusivity 
Denver (9m) Odds of gross motor delay lower for prolonged exclusive 
breastfed group vs never breastfed group (OR=0.67, CI: 0.54-
0.84), fine motor delay (OR=0.93, CI: 0.74-1.16) 
Strain 
(2008)137 
Obs, n=229 Maternal serum fatty 
acids 
Bayley (9m) PDI positively associated with total n-3 levels.(beta=28.26, 
p=0.03) 
Vohr (2006)138 Prospective 
cohort from 
RCT, n=1,035 
Some breast milk, no 
breast milk 
Bayley (18m) Breast milk group scored higher on MDI and PDI 
(MDI=79.9±18, PDI=84.6±19) than no breast milk group 
(75.8±16, 81.3±17) (p=0.07, 0.02) 
Morrow-
Tlucak 
(1988)139 
Obs, n=219 Breastfed >4 mos, ≤ 4 
mos, formula fed 
Bayley (6m, 12m) Breastfeeding duration positively associated with Bayley 
score at 12 mos. (>4 mos: 121.3, ≤4 mos: 116.0. formula: 
111.2, F=3.24, p=0.04), No significant differences at 6 mos. 
(114.0, 113.1, 110.8, F=0.55, NS). 
Ounsted 
(1988)140 
Obs, n=307 Breastfed 2, 6, 12 months, 
bottlefed 
Neurobehavioral score 
(2m, 6m, 12m) 
No differences at 2 mos.  Breastfed babies had higher 
neurobehavioral scores at 6 mos (F=4.5, p<0.05) and 12 mos 
(4.3, p<0.05).  Breastfed babies had higher motor scores at 12 
mos (F=4.8, p<0.01) but not social scores (F=1.5). 
Temboury 
(1994)141 
Obs, n=229 Breastfed ≤ 3 mos, 
formula fed or breastfed  
≤ 1 mo 
Bayley (18m) Comparing bottle-fed to breastfeeding, (odds of lower score) 
OR=1.86, p=0.044 for MDI.  OR=1.73, p=0.06 for PDI. 
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Vestergaard 
(1999)142 
Obs, n=1656 Breastfeeding duration, 
exclusivity 
General motor skills, 
fine motor skills, 
language (8m) 
Highest vs lowest breastfeeding category: crawling (RR=1.3, 
CI:1.0-1.6), pincer grip (1.2, 1.1-1.3), polysyllable babbling 
(1.5, 1.3-1.8) 
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3. Maternal supplementation studies 
Another way to examine the association between LCPUFA intake and infant 
development is to randomize pregnant or lactating women to dietary supplements containing 
LCPUFAs or a placebo.  While biologic measures like red blood cell DHA levels were often 
associated with supplementation, developmental outcomes tended to reflect no benefit from 
supplementation. 
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Table 2.3. Previous studies of LCPUFA supplementation in pregnant and lactating women and infant development 
Author 
(year) 
Study design 
(trial, 
observational) 
n 
Exposure Outcome measure(s) (age) Results 
Helland 
(2001)143 
Trial, n=262 Cod liver oil, corn oil Fagan (6m, 9m) Cod liver oil group did not differ from the corn oil 
group on novelty preference at 6 mos (mean=55.2 
(SD=4.5) vs 55.4 (3.7) or 9 mos (55.5 (3.8) vs 56.2 
(3.5)) 
Gibson 
(1997)144 
Trial, n=52 4 different doses of 
DHA algal oil, 
placebo 
Bayley (12m) Breast milk DHA content positively associated 
with MDI (r=0.29, p=0.04) but not PDI. 
Lauritzen 
(2005)145 
Trial,  n=175 Fish oil, olive oil, 
high fish intake 
Infant Planning Test (9m), MacArthur 
(12m), gross motor 
Fish oil group no better on problem solving than 
olive oil group, except for girls (mean=5.7±2.7 vs 
3.7±2.5, p=0.024).  Fish oil group performed 
worse on Vocabulary Comprehension 
(mean=54±37) than olive oil group (71±45, 
p=0.045), and on sentence complexity (boys) 
(mean=0.05 (25th-75th pct 0-3 vs 4.5 (0-10), 
p=0.043).  No differences in gross motor function. 
Jensen 
(2005)146 
Trial, n=227 DHA capsules, 
vegetable oil capsules 
Gesell Developmental Inventory (12m), 
Clinical Linguistic and Auditory 
Milestone Scale (CLAMS) (12m), 
Clinical Adaptive Test (CAT) (12m) 
DHA group did not perform better than control 
group on Gesell (mean=101.8±13.8 vs 99.5±13.3), 
CLAMS (100.6±14.6 vs 102.5±13.2) or CAT 
(109.0±10.7 vs 110.0±10.8) 
Judge 
(2007)147 
Trial, n=29 DHA bars, placebo 
bars 
Fagan (9m), infant problem solving 
(9m) 
DHA group had better problem solving but not 
recognition memory 
Tofail 
(2006)148 
Trial, n=400 Fish oil, soy oil Bayley (10m) Fish oil group scored no higher on MDI (102.5 vs 
101.5) or PDI (101.7 vs 100.5) than soy oil group 
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It remains an unresolved question whether breastfeeding duration or supplementation 
with LCPUFAs has a beneficial effect on infant neurodevelopment, despite the large number 
of studies that have addressed this issue.  A range of challenges confront studies in this area, 
including issues of study design, exposure measurement, outcome measurement, and 
appropriate consideration of confounders. 
Several aspects of study design may be partly responsible for the equivocal results of 
previous studies.  One challenge for the randomized studies in particular is generalizability.  
The vast majority of the research on the potential benefits of LCPUFA intake has adopted a 
randomized design at least in part to eliminate issues of confounding.  Many of these studies 
tested formulas that were specially developed for research purposes and not for wide 
consumption.  Infants who were compliant with the study protocols would have been fed 
exclusively the assigned formula product and not breast milk or other formulas.  Also, studies 
that include a breastfed comparison group do not randomize infants into breastfed or 
formula-fed groups due to ethical concerns.  Instead, the breastfed group is generally made 
up of infants whose mothers intend to breastfeed while the formula-fed groups are infants 
whose mothers intend to formula feed.104, 116  The infants who participated in these studies 
are not representative of formula-fed infants in the general population who often switch 
formula products one or more times during infancy.  Also, many infants in the general 
population are fed some breast milk and some formula, and their experience is generally not 
reflected in these studies.  Second, many studies have been very small, perhaps too small to 
detect an effect.  It is helpful to consider that smaller studies in this area more often find a 
positive association, while large studies tend to find no association.149  Third, some studies 
have been of limited duration, so an effect might not be observed because infants did not 
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consume the supplemented formulas long enough or were not followed long enough.  Given 
that fetuses accrue fatty acids through the placenta over a period of months during gestation 
and then most continue to take in fatty acids through breast milk or formula over the first 
weeks and months postnatally, it may not be surprising that supplement studies of short 
duration are unable to detect an effect. 
In terms of exposure, studies have varied widely in their choice of formulas fed to 
study infants, leading to incomparability across studies.  Formulas with low fatty acid content 
have been used in some studies, possibly limiting their ability to observe an effect.  Also, the 
balance of ingredients in the formulas used can affect how much of the LCPUFAs are 
available to the infant since n-3 and n-6 fatty acids compete for the same enzyme 
substrates.150  Overabundance of one fatty acid can suppress production of another.  As a 
result, the DHA content must be considered along with the content of other fatty acids when 
comparing studies.  Previous observational studies have generally employed fairly crude 
measures of exposure.  They have not thoroughly taken into account the wide variation in the 
extent to which infants are breastfed or formula fed and the differences in LCPUFA content.  
By extension, no previous studies have had the benefit of very detailed information about 
breastfeeding and formula use (formula with and without LCPUFAs) to examine dose-
response relationships.  Many randomized studies employed intent-to-treat analysis, normally 
a strength but which may obscure the variation in LCPUFA levels infants to which infants 
were exposed.15, 112  Observational studies of breastfeeding duration and exclusivity use 
varying exposure classification schemes, and this may explain some of the inconsistency in 
results. 
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Previous studies have been challenged in terms of outcome measurement.  The choice 
of outcome measures has varied widely across studies, so it is difficult to compare them.  
Studies have focused variously on mental or motor development, language development, 
visual attention, problem-solving, behavior, or intelligence and employed a variety of 
instruments to measure each.  In some studies, developmental outcomes were not measured 
using validated and reliable instruments.  Assessments of especially young infants are often 
not predictive of later outcomes like IQ or behavior, and some instruments are not designed 
to pinpoint variations within the normal range of cognition or behavior151, 152; low predictive 
value is one drawback of using an instrument like the Bayley Scales of Infant Development 
153-155
.  Another challenge is the timing of assessment.  Some instruments are only valid when 
applied to a narrow age window, and sometimes they are administered outside that window.  
Also, some previous studies employed tests of global development (e.g., Bayley) which may 
be insensitive to specific aspects of development that may be affected by LCPUFA intake or 
breastfeeding.  
A major challenge for previous studies has been control of confounding factors.  
Studies that compare breastfed children to formula-fed children are subject to criticism 
because of inadequate control of important confounding variables.  And, this is not just a 
problem for the observational studies.  Because it is generally considered unethical to 
randomize infants to breastfeeding versus formula feeding, most randomized studies only 
randomize within the formula fed group (to a LCPUFA formula or a control formula).  Thus, 
those studies are subject to some of the same confounding issues as observational studies.   
Many factors distinguish breastfed infants and formula fed infants aside from the 
amount of various fatty acids they may ingest.  First, breast milk and infant formulas differ in 
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their composition in more ways than just the fatty acid content.  For instance, human breast 
milk contains a variety of hormones, immunoglobulins, antibodies, antioxidants, proteins, 
and other substances.156  Infant formulas are designed to mimic some of these components 
but do not contain some of them or contain them in different form.156  It is possible that many 
of these substances could contribute to healthy neurodevelopment.  Second, the practice of 
breastfeeding itself involves enhanced opportunities for mother-infant bonding, not just a 
transfer of nutrients to the infant.  Strong bonds between mother and infant are important for 
optimal neurodevelopment.  Therefore, an association between the LCPUFA content of 
breast milk and enhanced development could be explained by bonding.  Third are the 
potential confounding factors underlying whether and how long an infant is breastfed versus 
formula-fed.  Whether an infant is exclusively breastfed, exclusively formula fed, or partially 
breastfed is determined by a number of factors, only some of which may be under the 
mother’s direct control.  These include attitudes about breastfeeding held by the woman and 
her family, counseling by health care providers, workplace policies, availability of 
information and help for feeding problems, and the ability for the woman and infant to be 
together.156, 157  Women who breastfeed tend to be of higher socioeconomic status including 
educational attainment and they tend to be older.158, 159  In the U.S., whites tend to choose 
breastfeeding more than other racial and ethnic groups.157, 158  Other factors can affect 
whether a woman chooses to feed her infant a formula with DHA and AA or one without, 
although little research has examined these factors.  These could include the cost (formulas 
with LCPUFAs cost more), knowledge about the purported benefits of LCPUFAs, whether 
she receives support from the Women, Infants and Children program which subsidizes 
enhanced formulas, and advice obtained from a health care provider or other trusted person.  
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These factors do influence breastfeeding initiation.158, 160-162  These psychosocial factors 
might be associated with the development of the infant as well and so could confound the 
association between LCPUFA intake and infant development.  And, a range of other factors 
(e.g., maternal diet, parity, depression) might be related to the composition of breast milk.  
These can confound an association between LCPUFA intake and developmental outcomes if 
they are associated with development as well. 
 
Opportunities for Future Research 
The limitations in previous studies leave a number of opportunities for future 
research.  Most previous studies of LCPUFA intake and infant neurodevelopment employed 
measures of visual acuity as the main outcome measures of interest.  However, recent studies 
have focused more on measures of global development.  This can help assess whether the 
effects observed on visual acuity translate into lasting effects on cognition, but this approach 
cannot ascertain whether specific aspects of development are differently affected.  Studies 
that assessed cognitive development most often employed the Bayley Scales of Infant 
Development even though the Bayley is a global measure of development and has limited 
predictive value.  No studies have examined the effect of fatty acid intake on the 
development of cognitive, visual and motor development using the Mullen Scales of Early 
Learning (Mullen).  Future studies should employ developmental measures like the Mullen 
that assess specific aspects of development, not global development, to help pinpoint what 
aspects of development may be affected. 
Well-designed observational studies that can account for the role of key confounders 
can help clarify whether there is a positive effect on child development due to LCPUFA 
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intake or from breastfeeding.  Addtionally, studies should be large enough to be able to 
detect an effect if one exists.  Exposure measurement methods should be enhanced to account 
for the variability in breast milk concentrations of LCPUFAs and the variety of infant 
formulas available.   
These opportunities are taken by the present study (Specific Aim 1).  The present 
study employs a prospective design and includes over 350 infants in follow-up to 12 months 
of age.  It employs very detailed exposure measurement techniques that incorporate breast 
milk LCPUFA content as well as formula LCPUFA content on a month-by-month basis.  
Finally, the developmental exams measure a number of specific developmental domains 
(e.g., language, motor, cognitive development). 
 
Maternal perinatal depressive symptoms, trait anxiety, and perceived stress and infant 
development  
Background and Significance 
A wide range of biological, environmental, and psychosocial factors can influence 
child development.  Maternal anxiety, perceived stress, and depression are several inter-
related psychosocial factors that have been found to negatively influence development.  
Many women experience significant psychological distress during pregnancy, with rates of 
mood disorders, post-traumatic stress disorders, and anxiety disorders reaching prevalence 
rates of 14%, 7.7%, and 6.6%, according to some studies.24, 163, 164  Approximately 10 to 15 
percent of women experience elevated postpartum depressive symptoms during at least some 
portion of the six months after delivery, although prevalence estimates vary widely from 5 to 
60 percent across studies.23, 165, 166  Pregnancy and the birth of a new infant are 
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psychoemotional milestones, and women may be more susceptible to psychological distress 
if they lack supportive influences or are experiencing other major life stresses at the same 
time.  Some of the strongest risk factors for elevated psychological distress during or after 
pregnancy include: low self-esteem, life stress, social support, marital relationship/status, 
history of depression, socioeconomic status, unplanned pregnancy, and infant 
temperament.167 
Anxiety and stress during pregnancy have been associated with more somatic 
complaints, low birth weight, preterm birth, and impaired infant orientation and self-
regulation.168-171  The physiologic pathways that connect these have not yet been well-
characterized but likely involve the interaction of cortisol and other hormones and the 
activity of the hypothalamic-pituitary-adrenal axis.172 
A number of studies have addressed the association between maternal perinatal 
psychological health and infant developmental outcomes.  The impetus for this area of 
research is the recognition that infant development is sensitive to the psychosocial 
environment and that these maternal symptoms may interfere with optimal care-giving.  
Several mechanisms could underlie this association and each is discussed below.  First, 
common genetic factors could underlie both psychological health and abnormal 
development, although research has yet to uncover any specific genetic factors.  Second, 
depressive symptoms, anxiety or stress can serve as a direct, negative psychosocial exposure 
for the infant. 
First, it is possible that common genetic factors underlie mood and stress responses 
and abnormal development.  Mother and child may share particular genotypes that 
predispose them to depression and poor neurodevelopment.  A number of studies have 
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identified possible genetic contributors to depression, although it is thought that 
environmental factors play a larger role; thus, gene-environment interactions make research 
in this area challenging.173  As examples, studies of depression have focused on the 
polymorphisms HTTPLR and BDNF V66M, and on a mutation for TPH2.174-176  Progress in 
understanding the genetic underpinnings of depressive symptoms has been disappointing; 
results of most studies have not been reproducible.  Nevertheless, it is conceivable that 
genotypes that affect neurotransmitter function, for instance, could contribute to the risk of 
mood disorders or elevated anxiety in adulthood as well as behavior during childhood. 
Second, it is possible that maternal affect and anxiety inhibit healthy bonding 
between mother and child which in turn inhibits healthy development.  The postpartum 
period is marked with major life changes and stresses for the new mother, most of which are 
offset by the great satisfactions a new baby also brings.  But some women experience 
difficulty with this transition due to a lack of or misplaced expectations, other stressful life 
events, or lack of social support.177-179  Conversely, women who exhibit many symptoms of 
depression are more likely to have low self-efficacy which can inhibit their ability to 
successfully serve in the maternal role.180, 181  In addition, a difficult or unhealthy child can 
exacerbate these circumstances.182, 183  Women who have trouble adapting to the maternal 
role may not interact optimally with their infant.  Previous studies have found that mothers 
who were depressed or anxious tended to be more irritable and hostile, display less 
engagement with their child, and to interact and play less with their child.36-39, 184  Infants of 
depressed mothers are more likely to be fussy, show fewer positive facial expressions, and 
are less vocal.185  It has been well established that positive parent or caregiver relationships 
are critical for healthy development during infancy.186 
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Critical review of the literature 
A handful number of studies have examined the association between maternal 
anxiety, depressive symptoms or stress (during pregnancy, postpartum) and developmental 
outcomes in very young children (i.e., global development, cognition).  Outcomes during 
infancy are of primary interest in this proposal, but there are relatively few studies in this age 
group.  The following inventory of the literature includes studies that assessed infants at up to 
24 months of age.  (Table 2.4). 
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Table 2.4. Previous studies of maternal depressive symptoms, anxiety, and stress and infant development 
Author (year), n 
 
Exposure Outcome measure(s), age Results 
Brouwers (2001)187, 
n=105 
State-Trait Anxiety Inventory (32w) Bayley (12m, 24m) High anxiety group had lower PDI at 12 m (89 vs 
97; t=2.35, p=0.02) than low anxiety group but not 
at 24m (98 vs 100; t=0.47, p=0.64).  High anxiety 
group had lower MDI at 24m (95 vs 106) than low 
anxiety group but not at 12m (97 vs 103; t=1.85, 
p=0.07). 
Carvalho (2008)188, n=36 State-Trait Anxiety Inventory, Beck 
Depression Inventory 
Bayley (12m) No significant correlation between anxiety or 
depression and Bayley scores (no details 
provided). 
Cornish (2005)189, n=112 Composite International Diagnostic 
Interview (4m, 12m), CES-D (4m, 
12m, 15m) 
Bayley (15m), Receptive-
Expressive Emergent 
Language Test (12m) 
Chronic but not brief depression associated with 
lower MDI scores (t=6.61, p<0.025), lower PDI 
(t=9.60, p<0.025), and proportion not yet walking 
(t=1.79, p<0.025) than never depressed.  No 
association between depression and total language 
quotient (F=0.33, p>0.10). 
DiPietro (2006)190, n=94 Profile of Moods Scale (24w 
gestation), State-Trait Anxiety 
Inventory (28w gestation), Daily 
Stress Inventory (24w gestation), 
Perceived Stress Scale (28w), Center 
for Epidemiologic Studies 
Depression Scale (32w), Pregnancy 
Experience Scale (32w) 
Bayley (24m) Pregnancy-specific distress associated with lower 
PDI (beta=-14.89, p<0.05). Prenatal depression 
and anxiety associated with better MDI and PDI 
scores (betas ranged 2.05-2.59, p<0.05). 
Galler (2000)38, n=226 General Adjustment and Morale 
Scale, Zung Depression and Anxiety 
Scale (7w, 6m) 
Griffiths Mental Development 
Scales (7w, 3m, 6m) 
Depressive symptoms at 7w associated with lower 
infant social and performance at 3m. Maternal 
mood at 6m associated with lower motor 
development at 6m 
Huizink (2003) [ref] Everyday Problem List, Pregnancy 
Related Anxieties Questionnaire-
Revised (15-17w, 27-28w, 37-38w) 
Bayley (3m, 18m) Daily hassles (espec at 15-17w) associated with 
lower MDI at 8 mos 
Kurstjens (2001) 191, 
n=1329 
Research Diagnostic Criteria, 
Schedule of Affective Disorders and 
Schizophrenia 
Griffiths Scales of Babies’ 
Abilities (20m) 
No association between postpartum depression or 
later depression or chronicity, severity or recency 
with cognitive outcomes. 
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Lyons-Ruth (1986)192, 
n=NA 
Center for Epidemiologic Studies 
Depression Scale (between 0-12m, 
18m) 
Bayley (12m) CES-D associated with MDI (r=-0.32) and PDI 
(r=-0.30) 
Murray (1993, 1996, 
1999)29, 31, 40, n=59 
Edinburgh Postnatal Depression 
Scale (6w), Research Diagnostic 
Criteria, Schedule of Affective 
Disorders and Schizophrenia (18m), 
psychiatric interview (2m) 
Piaget object concept (9m, 
18m), Reynell (18m), Bayley 
(18m) 
Depression associated with Bayley score among 
boys (interaction with gender R2=0.04, p<0.04).  
Depression associated with object concept (18m, 
not 9m) (χ2=6.20, p<0.05) 
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Many previous studies support the conclusion that perinatal depressive symptoms 
negatively affect cognition in children at least up to age 7, although whether effects can be 
seen during infancy remains unclear.  Also, it seems that chronic depressive symptoms 
continuing well into childhood may affect cognition concurrently, but perinatal symptoms 
may continue to exert a detectable effect itself as the child grows older.  Another theme 
apparent in previous research is that depressive symptoms may interact with other 
psychosocial contextual factors like socioeconomic status to produce the observed cognitive 
deficits.  A common theme in several studies is the interaction between postpartum 
depressive symptoms and infant sex; boys might be more vulnerable to the effects of 
postpartum depression.27, 29, 40, 191  However, large studies and more representative samples 
could help clarify whether this interaction is real. 
In contrast with depressive symptoms which often increase and subside over time, 
trait anxiety is a fairly stable characteristic of the individual.193  This is in contrast to state 
anxiety which is situational.  As a result, it is difficult to separate out the critical exposure 
period for trait anxiety since it may continue to affect the infant from before birth into 
childhood. 
It is important to consider the potential confounding role of the other maternal 
psychological factors (trait anxiety, perceived stress, depressive symptoms) in addition to 
factors like infant temperament, maternal self-esteem, and presence of the father or partner in 
studies of maternal psychological health and infant development.  Psychosocial factors like 
anxiety and stress have some shared biologic underpinnings with depressive symptoms.  
Some studies have taken a thorough look at the role of contextual factors like marital 
relationships and the family environment and have found that these factors appear to explain 
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at least part of what appears to be the long-term effect of perinatal depressive symptoms.194  
Some studies also looking for long-term effects have found that the effects of perinatal 
depressive symptoms are mediated by attachment during infancy—those who were insecure 
infants tended to become children with cognitive deficits or behavioral problems.194  And, the 
potential effect of anxiety seems to operate through parent-child interaction.37, 38 
Several gaps remain in understanding the effect of maternal perinatal psychological 
health on child development.  First, very few published studies conducted developmental 
assessments during infancy.  As a result, it is unclear whether there is an observable effect 
during the first year of life.  Second, many studies have been limited in size; several of the 
key studies in this area involved 120 infants or fewer and may have been underpowered since 
they have tended to find larger effects than large studies have found.  Third, previous studies 
have been inconsistent in their ability to control for potential confounding factors like the 
presence of a supportive partner or the other exposures (perceived stress, trait anxiety, 
depressive symptoms, accordingly).  Another shortcoming is that some past studies 
employed a cross-sectional design, making the temporal sequence between exposure and 
outcome uncertain.  Also, the instruments and the timing of their administration have varied 
widely across studies, making it difficult to compare results.  It is also possible that improved 
understanding of the specific aspects of development that are affected could be found if 
instruments were chosen to target those specific aspects and not broad assessments of 
development. 
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Opportunities for Future Research 
The limitations in previous research leave a number of opportunities for future 
research.  First, new studies should focus on development during infancy to determine 
whether there are observable effects during this early stage and should involve a sample size 
large enough to be able to detect an effect if one exists.  They should consider potential 
confounders like partner support and anxiety, which some previous studies did not consider.  
Another opportunity is to use developmental tests like the Mullen which examine specific 
aspects of development and have not been applied previously in this context.  The present 
study employs a prospective design and measures maternal psychological health during 
pregnancy and postpartum and follows infants to 12 months of age.  Finally, the study 
assesses infants using the Mullen to explore aspects of development that have not been 
previously examined in this context. 
 
Perinatal depressive symptoms and docosahexaenoic acid status 
Background and Significance 
Depression has been associated with low levels of n-3 fatty acids, particularly DHA, 
in red blood cell membranes and brain orbitofrontal cortex tissue of adults.43, 44, 195  
Pregnancy may exacerbate low DHA status because maternal stores of DHA are mobilized to 
support the rapid development of the fetal brain.49  If depressed women have lower 
circulating DHA levels, this could potentially limit the amount of fatty acids available to the 
infant via breast milk.  Women with elevated depressive symptoms postpartum have been 
shown to have lower plasma phospholipid levels of DHA than women who have few 
symptoms.196  The precise relationship between n-3 fatty acids and depressive symptoms is 
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only recently becoming better understood; DHA and EPA are involved in neural function 
(phospholipase A2 activity, neurotransmitter function, regulation of enzyme activity, 
inflammatory response, oxidative stress, and gene expression).197  The direction of the 
association between fatty acid levels and depressive symptoms is debatable.  It could be 
explained by diet (depressed individuals may consume a less healthy diet), by underlying 
abnormalities in how fatty acids are produced or utilized that both reduce fatty acid levels 
and induce depressive symptoms, by reduced synthesis or increased elimination of fatty acids 
among depressed individuals, or by deficiencies in fatty acid levels due to pregnancy or 
lactation that could trigger depressive episodes.197, 198  Ecologic studies have shown that 
populations with high levels of fish consumption tend to have lower rates of depressive 
symptoms, and within populations those with higher fish intake may be at lower risk.199-201  
The fatty acid content of breast milk is correlated with the content in the maternal diet.202  
Whether women who experience elevated perinatal depressive symptoms also have lower 
breast milk DHA levels has been examined in only one study; an ecologic study by Hibbeln 
found the average DHA content of breast milk to be strongly associated with national 
postpartum depression prevalence rates.42  In the postpartum period, maternal DHA stores are 
a major source of DHA via breast milk for the infant.  Approximately 73% of U.S. infants are 
breastfed for at least some time, and 12% are exclusively breastfed for the first 6 months.203  
If women suffering from perinatal depressive symptoms have lower circulating fatty acids 
levels or produce an inadequate supply of fatty acids in their breast milk, their ability to 
provide adequate LCPUFAs to their fetus or infant for brain development may be inhibited. 
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Critical Review of the Literature 
A handful of studies have noted lower DHA levels among women with postpartum 
depression, but the results have been inconsistent and none have examined DHA levels in the 
breast milk (Table 2.5).196, 204-206  A few clinical trials have evaluated whether n-3 fatty acid 
supplements might prevent perinatal depression or reduce symptoms, with mostly negative 
findings.207-211  Most have had very small sample sizes. 
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Table 2.5.  Previous Observational Studies of Perinatal Depressive Symptoms and DHA Status 
Author (year), n 
 
Depressive 
symptoms 
measure 
DHA measurement Results 
Browne (2006)206, 
n=80 
Composite 
International 
Diagnostic 
Interview 
Plasma 
phosphatidylcholine 
Percent of total n-3, EPA, DHA, n-6:n-3 ratio all 
unassociated with being in the Diagnosis, Screened 
High, or control group 
De Vriese (2003)204, 
n=48 
Diagnostic and 
Statistical Manual 
IV 
Serum phospholipids and 
cholesterol esters 
DHA lower in women who developed postpartum 
depression compared to controls (phospholipid, 
3.11% vs 4.22%, p=0.006) (cholesterol esters, 
0.38% vs 0.61, p=0.02) 
Makrides (2003)205, 
n=380 
Edinburgh 
Postnatal 
Depression Scale 
Plasma 
phosphatidylcholine 
A 1% increase in plasma DHA associated with 59% 
reduction in depressive symptoms 
Otto (2003)196, n=112 Edinburgh 
Postnatal 
Depression Scale 
Plasma 
phosphatidylcholine 
No association between depressive symptoms and 
DHA levels at delivery or for change in DHA 
postpartum.  Increase in DHA:EPA ratio was 
higher in non-depressed than depressed group 
(OR=0.90, p=0.04) 
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Opportunities for Future Research 
If women who experience elevated perinatal depressive symptoms also have lower 
DHA levels in their breast milk, then it would appear that perinatal depression could have 
both a psychosocial influence as well as a nutritional one on infants.  Future studies should 
examine depressive symptoms at multiple time points during pregnancy and postpartum in 
relation to breast milk DHA content. 
CHAPTER 3 
SPECIFIC AIMS, HYPOTHESES, AND CONCEPTUAL MODEL 
The following Specific Aims and Hypotheses build on previous research in this area and 
are presented with the goal of advancing understanding about the roles of LCPUFAs and 
maternal psychological health in infant development.  The Specific Aims and their 
corresponding hypotheses are reflected in the Conceptual Model in Figure 3.1:  
1- Examine the association between exposure to LCPUFAs, whether from breast milk or 
formula, and visual reception, language, and motor skills, and overall cognitive 
development at 12 months of age. 
Hypothesis – Infants exposed to low levels of certain LCPUFAs (i.e., DHA, AA) 
exhibit less advanced visual reception, language, and motor skills, and overall 
cognitive development at 12 months of age than infants exposed to high levels. 
2- Examine the association between: 
a.  maternal trait anxiety 
b. perceived stress 
c. perinatal depressive symptoms 
and visual reception, language, and motor skills, and overall cognitive development 
at 12 months of age. 
Hypothesis – Infants of women who demonstrate high levels of trait anxiety, 
perceived stress, or depressive symptoms perinatally exhibit less advanced visual 
reception, language, and motor skills, and overall cognitive development at 12 
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months of age than infants of women who demonstrate low levels of trait anxiety, 
perceived stress, or depressive symptoms. 
3- Examine whether women who experience elevated perinatal depressive symptoms 
have lower levels of DHA in their breast milk. 
Hypothesis – Women who have elevated depressive symptoms have lower DHA 
breast milk concentrations than women with fewer depressive symptoms. 
 
 
 
Figure 3.1. Conceptual Model for Each Specific Aim and the Hypothesized 
Relationships Between the Factors 
 
 
 
LCPUFAs 
-breastmilk 
-formula 
Maternal 
psychological 
health 
 
 
 
 
 
Infant 
development 
Feeding 
method 
Psychosocial factors, 
maternal characteristics 
and diet 
Aim 1 
Aim 2 
Aim 3 
CHAPTER 4 
METHODS 
Study Design 
Participant identification 
 The study population is derived from the PIN Study and the offspring of a portion 
of the women participants (Appendix 2).45  The goal of the PIN Study was to identify 
factors associated with preterm birth.  The goal of PIN Postpartum is to identify 
modifiable behaviors associated with high gestational weight gain and postpartum weight 
retention.  The present study employs a prospective cohort design.  (However, a 
component of Specific Aim 3 is cross-sectional in design.)  PIN Babies focuses on child 
developmental outcomes in relation to the prenatal and early childhood environment. 
All protocols were approved by the University of North Carolina (UNC) 
Biomedical Institutional Review Board; all participants provided written informed 
consent.  The dataset is property of the University of North Carolina at Chapel Hill 
Carolina Population Center and is provided for analysis only in de-identified form.  The 
University of North Carolina at Chapel Hill Public Health and Nursing Institutional 
Review Board and the National Institutes of Health Office of Human Subjects Research 
govern human subjects aspects of the present study.  An exemption from full IRB review 
was obtained from both entities. 
For the PIN Study, women were recruited from among pregnant patients at less 
than 20 weeks gestation seeking prenatal care at UNC Hospitals.  Women were ineligible  
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if they were pregnant with multiple fetuses, could not communicate in English, were 
under age 16, had no access to a telephone, or were intending to go elsewhere for future 
care or delivery.  Since the present study focuses largely on the infants resulting from 
pregnancies of women participating in PIN and because only the infants from the third 
wave of PIN enrollment (PIN3) were followed, the present study includes only women 
from PIN3. 
 Women (n=1,169) were eligible for PIN Postpartum if they completed the third 
wave of the PIN Study, agreed to be contacted after delivery and lived in the study area.  
Medical constraints (n=24), inability to recontact (n=207) or schedule (n=62), and refusal 
(n=187) resulted in 689 women who participated in a visit scheduled in the fourth 
postpartum month.  The 305 women who provided a breast milk sample at this visit were 
eligible for the analysis pertaining to Specific Aim 3.  Before the 12-month data 
collection visit, 45 became pregnant again and were ineligible to continue, 62 were 
unreachable, 29 moved from the study area, and 20 requested to leave the study.  The 
PIN Babies protocol began after PIN Postpartum began and 125 infants were ineligible to 
complete the protocol because they reached 12 months of age before the study began 
conducting the infant assessments in homes. 
Among the remaining 408 eligible maternal-infant pairs, some did not participate 
in the Mullen because the child was not present during the data collection (n=11, e.g. the 
mother completed the interview at her workplace), the child was asleep, sick, or fussy 
(n=21), the mother refused the child’s participation (n=8), there was not enough time 
during the visit (n=3), or various other reasons (n= 7).  The 358 infants who completed at 
least part of the Mullen were eligible for analyses pertaining to Specific Aims 1 and 2. 
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Methods for Study 
Data collection 
 During pregnancy, information about depressive symptoms was collected via self-
administered questionnaires before 20 weeks gestation and at 24-29 weeks gestation 
using the Centers for Epidemiologic Studies Depression (CES-D) scale.212  The CES-D is 
intended to measure depressive symptoms in general population samples.  The CES-D is 
designed as a short 20-item self-report tool applicable to the general population and has 
been shown to be useful in detecting depression in a variety of groups including pregnant 
women.  It is not designed for clinical diagnosis of major depressive disorder.  
Components of depressive symptomology included in the CES-D include: depressed 
mood, feelings of guilt and worthlessness, retardation of psychomotor activity, appetite 
loss, and disturbed sleep.212  
 The questionnaire before 20 weeks gestation included the State-Trait Anxiety 
Inventory (STAI), the Rosenberg Self-Esteem Scale, and the MOS Social Support 
scale.193, 213, 214  The trait score of the STAI is a measure of an individual’s general 
feelings of anxiety and is relatively stable over time, in contrast to state anxiety which is 
situational.193  Age, education, income and other demographic and lifestyle covariates 
were obtained via telephone at 17-22 weeks gestation.  Delivery information was 
obtained from the hospital record.  Preterm birth was defined as less than 37 completed 
weeks gestation at delivery, based on ultrasound if done before 20 weeks gestation or the 
date of the last menstrual period. 
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A home visit in the fourth postpartum month collected information on maternal 
and infant health and nutrition and updated information about family circumstances and 
maternal psychosocial health.  The interview included the Edinburgh Postnatal 
Depression Scale (EPDS), a screening tool for depressive symptoms, and the 10-item 
Perceived Stress Scale to measure the extent to which one’s circumstances are perceived 
as stressful.215, 216  Information was collected about the number of feedings per day the 
infant was breastfed or fed formula or other foods for each month since birth.  The 
specific names of up to two formulas were recorded for each month.   
Women who were still breastfeeding were asked to use a breast pump at around 
10 AM on the day of the postpartum visit to provide three 1.5 ml tubes of milk for 
storage at -80 degrees Celsius at the study office.  Samples were analyzed for fatty acid 
content by two laboratories.  Samples collected before April 1, 2005, were analyzed by 
the Collaborative Studies Clinical Laboratory at the University of Minnesota Medical 
Center, Fairview (Minneapolis, Minnesota).  This lab was unable to complete the analysis 
for the second batch of samples, so those collected after April 1, 2005, were analyzed by 
the Clinical Nutrition Research Center, UNC (Chapel Hill, North Carolina). 
When infants reached 12 months of age, trained PIN Babies study staff scheduled 
a visit to administer the Mullen Scales of Early Learning (Mullen) following procedures 
outlined in the Mullen manual.217  The Mullen assesses cognitive functioning in children 
up to 68 months of age.   
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Exposure Measurement 
1. Breastfeeding and LCPUFAs 
Infants were classified as to the method by which they were fed: exclusively 
breastfed, almost exclusively breastfed, partially breastfed, or formula fed for each of the first 
4 postnatal months individually and combined: 
 
Exclusively breastfeeding: 
Breastfeeding only, neither other liquids nor solids 
Frequency of breastfeeding at the mth month of age >= 1 time/day and frequency of 
feeding other liquids or solids at the mth month of age = 0 times/day 
 
Almost exclusive breastfeeding: 
Breastfeeding, plus 1 or fewer times per day feeding any other liquids or solids 
Frequency of breastfeeding at the mth month of age >= 1 time/day and frequency of 
feeding formula at the mth month of age <= 1 time/day 
 
Partial breastfeeding: 
Breastfeeding, plus feeding other liquids or solids 
Frequency of breastfeeding at the mth month of age >= 1 time/day and frequency of 
feeding formula at the mth month of age > 1 time/day 
 
Formula feeding: 
Formula feeding only 
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Frequency of breastfeeding at the mth month of age = 0 times/day and frequency of 
feeding formula at the mth month of age > 1 time/day 
 
It is ideal to use a categorization scheme that differentiates among infants who are not 
exclusively breastfed, and similar schemes are used in many observational studies that have 
detailed breastfeeding information available.121, 218  It also parallels the recommendations of 
the World Health Organization and the Interagency Group for Action on Breastfeeding.219, 220 
The concentration of fatty acids in commercially available infant formulas was 
obtained from the U.S. Department of Agriculture Nutrient Database for Standard Reference 
(and for one formula, from the manufacturer’s website).221, 222  Forty-one women responded 
to questions about formula use with information that was ambiguous as to whether they were 
using a product with DHA and AA added.  Several answer choices on the data collection 
form did not distinguish between traditional or enhanced versions of the same formula, so it 
was not possible to determine which product was fed.  Twenty-seven of the 41 women were 
successfully recontacted to clarify their formula choices, and 26 women were able to clarify 
which formula they had used. 
The concentration of fatty acids in breast milk was obtained via laboratory 
analysis previously described.  (In addition to serving as an exposure measure for 
Specific Aim 1, the concentration of DHA in breast milk also serves as the dependent 
variable for Specific Aim 3). 
In addition to the laboratory values for the concentration of DHA and AA in 
breast milk, we calculated variables for exposure to DHA and AA using a composite of 
the breast milk values and the concentrations in the formulas fed during the 4 months.  To 
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account for variation in feeding method across months, the breast milk and formula 
values were weighted by the feeding method for each month: 
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Where, 
m=month since birth 
µ=concentration of the fatty acid of interest in breast milk (b) or infant formula (f) (units - % 
of total fatty acids) 
k=feeding pattern in m 
 1, if exclusive or almost exclusive breastfeeding 
 0.5, if partial breastfeeding 
 0, if formula feeding 
f=formula product (Fi≤2) 
 
For each month of exclusive breastfeeding or almost exclusive breastfeeding, the month 
was assigned the value for the DHA or AA concentration from the breast milk laboratory 
analysis.  Each month of formula feeding was assigned a fatty acid value based on the 
concentration in the particular formula product fed that month.  If more than one formula 
was fed that month, an average of the values for the 2 most often fed formulas served as 
the fatty acid value for that month.  Each month of partial breastfeeding was assigned a 
value that is one-half the laboratory value for the breast milk plus one-half the average 
formula value (up to 2 formulas) for that month.  Continuous DHA and AA exposure 
variables for all 4 months combined were calculated by summing the monthly values.   
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2. Maternal perinatal depressive symptoms, trait anxiety, and perceived stress 
Continuous scores from the trait anxiety scale of the STAI were categorized into 
tertiles based on their observed distribution in the study participants.  The trait anxiety 
scale measures the individual’s general approach to stressful circumstances, which is 
considered stable over time.193  The scale consists of 20 items, scored on a scale of 1 to 4 
(Not At All to Very Much So) to form a composite.  Cronbach’s alpha ranged 0.89 to 
0.92.193 
Continuous scores from the Perceived Stress Scale (PSS) were categorized into 
tertiles based on their observed distribution in the study participants.  The PSS is intended 
to measure the degree to which an individual perceives life situations to be stressful.216  It 
contains 10 items which are scored by summing scores from 0 to 4 (Never to Very Often) 
for the negative items and reversing the scoring for the positive items.223  The PSS has 
been found to correlate moderately with counts of life events, social anxiety, and 
depressive symptoms, although the PSS and the CES-D do not measure the same 
constructs.216  Test-retest correlations ranged 0.55 to 0.85, depending on the time between 
assessments.216 
Each item on the CES-D  is scored on a four-point scale that ranges from “rarely 
or none of the time” to “most or all of the time” the respondent felt or experienced the 
particular item during the previous week.224  The early work done to evaluate the 
instrument found moderate test-retest correlations (range: 0.48-0.67) between 
administrations of the instrument, which might be expected since the instrument is 
focused on feelings over the previous week which would shift over time.212  The CES-D 
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has been found to discriminate well between individuals under care for depression and 
those in the general population: 70 percent of patients and 21 percent of a general 
population samples scored above 16.212  The 16/17 cutpoint for the CES-D was chosen 
for the present study because several studies have reported reduced specificity of the 
CES-D using the 15/16 cutpoint for pregnant women because some symptoms of 
pregnancy (e.g., fatigue) are similar to CES-D components.225-227 
Similar to the CES-D, the EPDS is designed to screen for depression but some of its 
10 items are focused on circumstances related to pregnancy and motherhood.  It is not 
intended to substitute for a thorough psychiatric evaluation and a high score does not 
necessarily equate with clinical diagnosis of Major Depressive Disorder.  Instead, the EPDS 
in intended to be administered by research or clinical staff with minimal training and in a 
variety of settings, and it is quick to administer.228  In its initial validation study, at a score of 
13 or above, the EPDS was able to identify all women with Definite Major Depressive Illness 
and two-thirds of the women with Probable Major Depressive Illness.228  Sensitivity for 
detection or major or minor depressive illness was 86 percent and the positive predictive 
value was 73 percent.  Specificity was 78 percent.  At the cutpoint of 9/10, the EPDS was 
estimated to miss only 10 percent of depression cases.228  Expanding on the initial validation 
work by Cox et al., several others have validated this cutpoint in previous studies.  It detects 
minor depression or increases the sensitivity of the instrument for depression and has been 
shown to identify cases of clinical depression with more than 90% sensitivity.228-231 
For the purposes of Specific Aim 2, a variable was constructed to examine 
depressive symptoms across both the antepartum and postpartum periods based on scores 
on the CES-D and EPDS.  Women were classified as having few depressive symptoms 
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postpartum (EPDS=0-9) (regardless of antepartum symptoms), minor or major depressive 
symptoms only during the postpartum period (EPDS > 9 and both CES-D scores=0-16), 
and minor or major depressive symptoms during both the postpartum and antepartum 
periods (EPDS > 9 and at least one CES-D score > 16).  For the purposes of Specific Aim 
3, each CES-D measure and the EPDS were used as individual exposure measures, and a 
composite of the three measures (a count of the number of times a woman scored above 
the cutpoint on an assessment) was also used. 
 
Outcome Measurement – Infant Development 
Raw scores from the five Mullen sub-scales were converted to age-specific t-
scores for the four cognitive sub-scales (Visual Reception, Fine Motor, Receptive 
Language, Expressive Language) and the Gross Motor sub-scale of the Mullen.  The 
cognitive sub-scale scores were summed and converted to a standard Early Learning 
Composite (Composite) score following procedures outlined in the manual.217  All 
analyses adjusted for preterm status; however scores were not directly adjusted for 
gestational age at birth because we found the procedure recommended in the manual 
potentially overcorrected scores for preterm infants.  The age-adjusted mean score for 
preterm infants was higher than the mean score for term infants for the Composite and all 
of the Mullen sub-scales except the Fine Motor scale, although the difference was 
statistically significant for the Receptive Language sub-scale only (age-adjusted mean 
Receptive Language t-score for preterm infants=49.2, term infants=45.8, t=2.5, p=0.01). 
Test-retest reliability for each subscale has been found to be high, ranging r=0.82-
0.85 for children under 24 months of age.217  The Mullen subscales have been found to 
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have high correlations with the Bayley MDI (range=0.53-0.59) and less so with the PDI 
(range=0.21-0.52), indicating that the Mullen is more focused on cognitive abilities than 
psychomotor.217  Since the Mullen is intended to be an assessment of specific abilities 
and not a test of global development, it makes sense that the Mullen and Bayley MDI 
have between 28 and 35 percent of the variance between the measures overlapping based 
on the squared intercorrelations.217  The predictive value of the Mullen remains unclear, 
but it has been used to identify language delays in children who later were diagnosed 
with Autism Spectrum Disorders.232  In another study, the Mullen was able to identify 
approximately two-thirds of 4-year-old children who went on to fail kindergarten, first, or 
second grade.233 
 
Covariates 
A range of possible covariates were identified based on previous studies and 
evaluated initially through the use of Directed Acyclic Graphs (DAG).  DAGs are causal 
graphs that can be used to represent relationships between exposure, outcome and 
confounding factors, based on underlying assumptions about the biological mechanisms 
involved 234, 235.  The very basic concepts needed to interpret the DAGs for the present study 
are described here.  (Articles by Robins and Greenland et al. provide additional discussion 
about the use of DAGs since this topic cannot be adequately covered here.234, 235)  The 
exposure and outcome are connected by a single-headed arrow with a question mark, 
indicating the potential association under study.  Variables represented in the diagram are 
connected by arrows to indicate the direction of various associations.  A variable connecting 
the exposure and outcome via a series of arrows consistently pointing from the direction of 
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the exposure toward the outcome is considered to be on the causal path (they are mediators).  
A confounder is represented by a variable with arrows leading from it to both the exposure 
and outcome (either directly or through one or more other variables).  A collider is a variable 
that has two or more arrows pointing into it.  DAGs can be helpful to identify the minimally 
sufficient set of confounders that could be controlled for in an analysis and to avoid inducing 
confounding by adjusting for variables on the causal path.  Variables that are not measured in 
the present study are represented by the notation “U” for “unmeasured.”  DAGs 1-3 pertain 
to Specific Aims 1-3, respectively  
The presence of effect measure modification was assessed using multiple partial F-
tests.  Where no notable effect measure modification was detected, the change-in-estimate 
approach was used to refine the list to the variables to be included as confounders in 
regression models.  The confounders included in the final models are presented in Table 4.1, 
along with their source and classification scheme.   
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Table 4.1. Potential covariates for each Specific Aim, sources, classification schemes 
Covariate Description Specific Aim 
 
Source Classification scheme 
Race and 
ethnicity 
Maternal race and 
ethnicity 
1 Phone interview 17-22 
weeks gestation 
0= All others 
1= White, non-Hispanic 
Maternal 
education 
Maternal education 1, 2, 3 Phone interview 17-22 
weeks gestation 
0=0-12 years 
1=13-16 years 
2=17+ years 
Maternal age Maternal age 3 Phone interview 17-22 
weeks gestation 
0=17-20 
1=21-30 
2=31-47 
Preterm birth Preterm birth was 
defined as less than 37 
completed weeks 
gestation at delivery, 
based on ultrasound if 
done before 22 weeks 
gestation or the date of 
the last menstrual period. 
1, 2 Obstetric record 0=<37 completed weeks 
1= >= 37 completed weeks 
Feeding method Degree of breastfeeding 
or formula feeding, first 
4 post-natal months 
combined 
1 Interview 4th month 
postpartum 
2=Exclusive or almost exclusive 
breastfeeding 
1=Partial breastfeeding 
0=Formula feeding 
Maternal anxiety Trait anxiety 2 Self-administered 
questionnaire at <20 weeks 
gestation 
1=0-<31 
2=31-<40 
3=40+ 
Maternal stress Cohen’s Perceived Stress 
Scale 
2 Interview 4th month 
postpartum 
1=0-<17 
2=17-<23 
3=23+ 
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Maternal smoking Ever smoked cigarettes 
during specified time 
period 
1, 3 Phone interview 27-30 
weeks gestation 
Interview 4th month 
postpartum 
0=never smoked during 
pregnancy or to 4 months 
postpartum 
1=ever smoked during 
pregnancy or to 4 months 
postpartum 
Parity The number of prior live 
or stillbirths 
1 Phone interview 17-22 
weeks gestation 
0=none 
1=1 or more 
Maternal self-
esteem 
Rosenberg’s self-esteem 
scale 
2 Self-administered 
questionnaire at <20 weeks 
gestation 
1=0-<50 
2=50-<56 
3=56+ 
Infant sex Infant sex 1 Delivery record 0=female 
1=male 
Maternal n-3 
intake 
Estimate of daily intake 
of n-3 fatty acids 
3 Food Frequency 
Questionnaire at 24-29 
weeks gestation 
Continuous 
Presence of 
spouse or partner 
Currently married or 
living with partner 
3 Interview 4th month 
postpartum 
0=no 
1=yes 
Laboratory Variable for laboratory 1, 3 Laboratory record 0=University of North Carolina 
1=University of Minnesota 
2=University of Minnesota 
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Data Analysis 
Overview 
The conceptual model and specific aims laid out previously provide the framework 
for the analysis plan.  Some common procedures apply to all specific aims.  First, all 
exposure variables, outcome variables, and potential covariates were examined using 
univariate techniques to assess the degree of missing data and characteristics of the 
distribution of each (e.g., mean, median, mode, standard deviation, range, skewness, 
kurtosis).   
Second, based on the previously constructed exposure and outcome variables, 
bivariate analyses (chi-square, simple linear regression, odds ratios) explored unadjusted 
associations between exposures and outcomes.  Multiple partial f-tests checked for the 
presence of effect measure modification by the potential covariates included in the DAGs.  
Then, an assessment was done for whether there was potential confounding by each potential 
covariate using the change-in-estimate approach.  Confounders were defined as variables 
identified via the DAGs and subsequently via the change-in-estimate approach.  Finally, 
multivariable linear regression was used to examine exposure-outcome relationships.  
Graphical methods assisted in checking the assumptions underlying linear regression.  For 
Specific Aim 3, the dependent variable (DHA) was log transformed to provide a better fit.  
Next, multiple imputation was used to fill in values for missing data for the analyses 
pertaining to Specific Aim 2 so that all women in the dataset had three depression scores (2 
during pregnancy and 1 in the fourth postpartum month).  Some infants had one or more 
missing sub-scale scores for the Mullen, and these were imputed as well as other covariates 
with a small proportion of missing values.  Multiple imputation is a good approach when 
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more than one variable has missing data to be imputed.236, 237  It will increase the statistical 
power and also decrease potential bias that might result if analyses relied on only complete 
case analysis, if the imputation model is well-specified.  The Markov chain Monte Carlo 
method using SAS procedures (PROC MI) produced 10 replications of the dataset with 
missing values imputed.  The imputed datasets were analyzed using SAS (version 9.1) linear 
regression procedures and combined with PROC MIANALYZE to produce the effect 
estimates reported.238 
 
Directed Acyclic Graphs 
The DAG displayed in Figure 4.1 guided the analysis for Specific Aim 1.  The box 
labeled “LCPUFA intake” corresponds to the calculated LCPUFA variables described 
previously.  While those calculations consider the role of feeding method, they do not 
adequately account for the important differences between infants who are breastfed and those 
who are formula fed.  As a result, feeding method was treated as a confounder in this 
analysis.  Maternal diet is an important influence on breast milk fatty acid composition, and 
socioeconomic status and race and ethnicity both influence breastfeeding duration and 
formula choice, so these all should be considered as potential confounders given their 
association with developmental outcomes.  The other covariates noted in Figure 4.1 were 
handled by controlling for the potential confounders just mentioned. 
 
  61 
Figure 4.1. Directed Acyclic Graph #1– Specific Aim 1 
 
 
Figure 4.2 displays the DAG for Specific Aim 2.  Taking into consideration all the 
potential paths and seeking the smallest possible set of potential covariates for adjustment, 
the following list of potential confounders will be considered: infant temperament, maternal 
stress, maternal anxiety, social support, marital relationship, and maternal self-esteem. 
 
LCPUFAs Infant 
development 
Feeding 
method 
Smoking 
Genes (U) 
Maternal IQ (U) 
SES 
Maternal diet/fatty 
acid stores 
Race/ethnicity 
Parity 
? 
Bonding/attachment/
parenting (U) 
Maternal 
depression 
Gestational age 
Infant sex 
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Figure 4.2. Directed Acyclic Graph #2– Specific Aim 2 
 
 
 
For Specific Aim 3, the breast milk LCPUFA values only (not incorporating formula 
values), in continuous form, will serve as the dependent variables for this component on 
depressive symptoms and DHA content of breast milk (while recognizing the uncertainty 
about the temporal direction of this potential association).  Potential confounders were 
identified from previous literature.  The direction of the association between maternal diet 
and depressive symptoms is debatable.  As a result, models initially included diet but were 
reanalyzed with diet excluded to observe whether effect estimates changed. 
Maternal 
psychological 
distress 
Infant 
development 
Feeding 
method 
Life stress 
Self-esteem 
Gestational age Infant temperament 
Fatty acid 
intake 
Marital relationship 
Social/partner support 
? 
Bonding/attachment/ 
parenting (U) 
Anxiety 
Maternal diet 
Genes (U) 
# siblings 
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Figure 4.3. Directed Acyclic Graph #3– Specific Aim 3 
 
 
 
Maternal 
perinatal 
depressive 
symptoms 
Breast milk 
DHA 
U 
Maternal age 
Parity 
Partner/spouse 
? 
Smoking 
Maternal diet 
Education 
CHAPTER 5 
RESULTS 
Specific Aim 1: Long-chain polyunsaturated fatty acids in breast milk and formula and 
infant cognitive development 
 
Introduction 
The role of certain dietary long-chain polyunsaturated fatty acids (LCPUFAs) in 
healthy brain development has been of interest for several decades.  Fatty acids are important 
constituents of cell membranes, and LCPUFAs, especially docosahexaenoic acid (DHA), 
accumulate in large concentration in the developing brain of the infant, particularly in the 
gray matter and in the rod photoreceptors of the retina.7-10  DHA and other LCPUFAs like 
arachidonic acid (AA) are present in human breast milk.  A number of studies have found 
that feeding LCPUFA-containing formulas is associated with positive outcomes like 
improved global development; other studies have found no association with development, yet 
these fatty acids are added to many commercially available infant formulas.15, 104, 110-113, 116, 
117, 221, 239, 240
 
Inconsistency in results may be because of variation in the formulas fed to study 
participants, diversity in the definition of comparison groups, differences in outcome 
measurements used, sample size constraints, limited length of follow-up, and poor control of 
confounding.  Most studies in this area have been infant feeding trials often involving only 
preterm infants.  A randomized design can be an advantage, but these studies may have  
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limited generalizability because they rely on intent-to-treat analysis by group rather than 
effective dose of LCPUFAs reaching the infant and are not based on the actual breast 
feeding patterns reflecting the combinations of breast milk and formulas infants are fed in 
the general population.  Most studies used a measure of global development like the 
Bayley Scales of Infant Development which is unable to separately evaluate specific 
aspects of development, like language, to see whether some aspects of development are 
benefited more than others.   
Because only 12% of U.S. children are exclusively breastfed at 6 months of age, 
most children are introduced to formula at some point in infancy.203  As a result, both 
breast milk and infant formulas can be important sources of LCPUFAs in infant diets, but 
their relative contribution changes with shifts in feeding method across infancy.  We 
found no studies that examined developmental outcomes in relation to the LCPUFA 
content of both breast milk and formula while considering changes in feeding method 
across time. 
Improved understanding of the role of LCPUFAs in development could help 
refine guidance about infant feeding practices.  This study addresses three distinct 
questions: 1) is the extent of breastfeeding during the first 4 postnatal months associated 
with visual reception, language, and motor skills, and overall cognitive development as 
measured via the Mullen Scales of Early learning (the Mullen) at 12 months of age?  2) Is 
the LCPUFA concentration of breast milk associated with development (Mullen scores) 
among infants who are exclusively breastfed?  3) Is the LCPUFA concentration of the 
breast milk and formulas infants are exposed to during the first 4 postnatal months 
associated with development (Mullen scores)?  
  66 
 
Methods 
Study population 
Data were collected as part of the Pregnancy, Infection, and Nutrition Study 
(PIN) and its postnatal follow-up components, PIN Postpartum and PIN Babies.  The 
goal of the PIN Study was to identify factors associated with preterm birth.45  The 
goal of PIN Postpartum is to identify modifiable behaviors associated with high 
gestational weight gain and postpartum weight retention.  PIN Babies focuses on 
child developmental outcomes in relation to the prenatal and early childhood 
environment.  All protocols were approved by the University of North Carolina 
(UNC) Biomedical Institutional Review Board; all participants provided written 
informed consent.   
 Women (n=1,169) were eligible for PIN Postpartum if they completed the 
third wave of the PIN Study, agreed to be contacted after delivery and lived in the 
study area.  Medical constraints (n=24), inability to recontact (n=207) or schedule 
(n=62), and refusal (n=187) resulted in 689 women who participated in a home visit 
in the fourth postpartum month.  The PIN Babies protocol began after PIN 
Postpartum began; as a result, 125 infants were ineligible to continue to PIN Babies.  
Also, 45 women became pregnant again, 62 were unreachable, 29 moved from the 
study area, and 20 requested to leave the study.  Among the remaining 408 eligible 
maternal-infant pairs, some did not participate in the Mullen assessment during a 
home visit at 12 months of age because the child was not present during the data 
collection (n=11, e.g. the mother completed the interview at her workplace), the child 
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was asleep, sick, or fussy (n=21), the mother refused the child’s participation (n=8), 
there was not enough time during the visit (n=3), or various other reasons (n= 7). 
 
Exposure measurement 
The first home visit collected information for each month about the number of 
feedings per day the infant was breastfed or fed formula or other foods. 
Women who were still breastfeeding were asked to use a breast pump at 
around 10 AM on the day of the postpartum visit to provide three 1.5 ml tubes of milk 
for storage at -80 degrees Celsius at the study office.  Samples were analyzed for fatty 
acid content by two laboratories.  Samples collected before April 1, 2005, were 
analyzed by the Collaborative Studies Clinical Laboratory at the University of 
Minnesota Medical Center, Fairview (Minneapolis, Minnesota).  This lab was unable 
to complete the analysis for the second batch of samples, so those collected after 
April 1, 2005, were analyzed by the Clinical Nutrition Research Center, UNC 
(Chapel Hill, North Carolina).  Fatty acid extraction was performed on 0.5 ml 
samples of breast milk mixed with 0.5 ml 0.9% saline using the method of Bligh and 
Dyer.241  The chloroform phase was transferred to a clean tube and evaporated to 
dryness under a nitrogen flow.  Residual lipids were saponified and fatty acids were 
transmethylated by sequentially adding 1ml 4.25% NaOH in CHCl3:MeOH (2:1, v/v) 
and 1N HCl in saline.242  After vigorous mixing, the samples were centrifuged at 
1500g for 5 minutes.  The fatty acid methyl esters in the lower phase were evaporated 
to dryness under nitrogen and then resuspended in 50 µl undecane and analyzed by 
capillary gas chromatography (injector 240°, detector 280°).  To check the efficacy of 
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the extraction, 0.1 mg 17:0 standard (diheptadecanoyl phosphatidylcholine) was 
added.  The individual fatty acids were identified by comparison with authentic 
standards (Nu Chek Prep, Elysian, MN).  Data were analyzed using Perkin Elmer 
Totalchrom Chromatography Software, version 6.2 (Somerset, NJ). 
Infants were classified as to the method by which they were fed: exclusively 
breastfed, almost exclusively breastfed, partially breastfed, or formula fed for each of 
the first 4 postnatal months individually and combined.  Infants who were breastfed 
for all feedings per day were considered exclusively breastfed.  Infants who were 
breastfed and also supplemented 1 formula feeding per day were considered almost 
exclusively breastfed.  Infants who were fed infant formula for all daily feedings were 
considered formula fed.  All other infants were partially breastfed.   
The specific names of up to two formulas were recorded for each month.  The 
concentration of fatty acids in commercially available infant formulas was obtained 
from the U.S. Department of Agriculture Nutrient Database for Standard Reference 
(and for one formula, from the manufacturer’s website) which was used to assign 
values for the fatty acid concentrations for each formula.221, 222  
We used a combination of the laboratory values for the concentrations of 
DHA and AA in breast milk and concentrations in formula to create composite DHA 
and AA exposure variables to reflect feeding patterns over the first 4 months.  To 
account for variation in feeding method across months, the breast milk and formula 
values were weighted by the feeding method for each month: 
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Where, 
m=month since birth 
µ=concentration of the fatty acid of interest in breast milk (b) or infant formula (f) (units - 
% of total fatty acids) 
k=feeding pattern in m 
 1, if exclusive or almost exclusive breastfeeding 
 0.5, if partial breastfeeding 
 0, if formula feeding 
f=formula product (Fi≤2) 
 
For each month of exclusive breastfeeding or almost exclusive breastfeeding, the 
month was assigned the value for the DHA or AA concentration from the breast milk 
laboratory analysis.  Each month of formula feeding was assigned a fatty acid value 
based on the concentration in the particular formula product fed that month.  If more 
than one formula was fed that month, an average of the values for the 2 most often 
fed formulas served as the fatty acid value for that month.  Each month of partial 
breastfeeding was assigned a value that is one-half the laboratory value for the breast 
milk plus one-half the average formula value (up to 2 formulas) for that month.  
Continuous DHA and AA exposure variables for all 4 months combined were 
calculated by summing the monthly values.   
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Outcome measurement 
When infants reached 12 months of age, trained PIN Babies study staff 
scheduled a visit to administer the Mullen Scales of Early Learning (Mullen) 
following procedures outlined in the Mullen manual.217  The Mullen assesses 
cognitive functioning in children up to 68 months of age.  Raw scores were converted 
to age-specific t-scores for the four cognitive sub-scales (Visual Reception, Fine 
Motor, Receptive Language, Expressive Language) and the Gross Motor sub-scale of 
the Mullen.  The cognitive sub-scale scores were summed and converted to a standard 
Early Learning Composite (Composite) score following procedures outlined in the 
manual.217  Scores were not directly adjusted for gestational age at birth because we 
found that the procedure recommended in the Mullen manual overcorrected scores for 
preterm infants.243  However, an indicator of preterm status was included in 
regression models. 
 
Covariate measurement 
 Several potential covariates were measured during pregnancy. Data on 
maternal age, education, and other demographic and lifestyle covariates were 
obtained via telephone at 17 to 22 weeks gestation.  A self-administered questionnaire 
before 20 weeks gestation included the State-Trait Anxiety Inventory (STAI) to 
measure trait anxiety.193  Parity was defined as the number of prior live or stillbirths.  
Delivery information was obtained from the hospital record.  Preterm birth was 
defined as less than 37 completed weeks gestation at delivery, based on ultrasound if 
done before 22 weeks gestation or the date of the last menstrual period.  At the first 
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home visit, women were asked about current smoking and family income and 
completed the Edinburgh Postnatal Depression Scale to assess depressive 
symptoms.228 
 
Statistical analysis 
We built three sets of models corresponding to the three research questions 
mentioned previously: 
-Breastfeeding models: we compared infants who were in the exclusively or 
almost exclusively breastfed groups for the first 4 postnatal months to those who 
were formula fed among each Mullen sub-scale and the Composite score.  Infants 
who were partially breastfed were also compared to formula fed infants. 
-Breast milk models: we examined the association between the DHA and AA 
concentration of the breast milk samples and Mullen scores among infants who 
were exclusively breastfed for the first 4 postnatal months combined. 
-Combined models: we used the constructed variables that incorporated breast 
milk and infant formula DHA and AA concentration according to the feeding 
method for each month, and these were examined in relation to Mullen scores. 
 
Linear regression models were used to examine these associations.  SAS software 
version 9.1 was used for all analyses.238  The residuals were found to be approximately 
normally distributed using kernel density and Q-Q plots and to have constant variance 
using the White test.244 
  72 
Potential covariates were identified a priori based on previous studies and 
constructed Directed Acyclic Graphs.234, 235  Adjusted models incorporated confounders 
that resulted in a change of greater than 10% in the beta coefficient for the exposure 
variable when removed from a model.  Potential covariates considered included: income 
(categorical variable for percentage of the federal poverty level), education (high school 
or less, college, more than college), maternal age (16-20, 21-30, 31+), parity (0 or 1+), 
race and ethnicity (white, non-Hispanic versus all others), infant sex, preterm birth, trait 
anxiety (tertiles), and depressive symptoms (EPDS 0-9 versus 10+).  Multiple partial F-
tests checked for the presence of effect measure modification. 
Because some women who breastfed for at least several weeks did not provide a 
breast milk sample, we explored the effect on our results of imputing missing fatty acid 
values for those women (n=88, 24.6% of women). The Markov chain Monte Carlo 
method using SAS procedures (PROC MI) produced 10 dataset replications with missing 
values imputed, and these were combined with PROC MI ANALYZE for linear 
regression analysis.236-238 
 
Results 
To be eligible for the present analysis, infants completed at least one sub-scale of 
the Mullen at (n=358; 343 completed all sub-scales).  All infants had information 
available about feeding method.  Overall, 57.8% of infants were exclusively or almost 
exclusively breastfed, 31.3% partially breastfed, and 10.9% formula fed for the 4 months.  
When examined month-by-month, it is apparent that breast feeding gradually declined 
while formula feeding increased.  By the time of the first home visit, 68 (19.0%) of the 
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358 women eligible for this analysis had discontinued breastfeeding, 231 (64.5%) 
provided a breast milk sample (230 were analyzable), 17 (4.7%) were unable to provide a 
sample, and 3 (0.8%) refused participation in breast milk collection. 
Women who discontinued breastfeeding before the visit or were unable to refused 
to provide a sample were more likely to smoke (OR=7.8, 95% CI: 3.5, 17.3), have a 
preterm infant (OR=3.0, 95% CI: 1.5, 6.3), have a 12th grade or less education (OR=7.9, 
95% CI: 3.7, 17.0), and be other than white, non-Hispanic (OR=3.4, 95% CI: 1.9, 6.3), 
compared to women who provided a breast milk sample. 
Table 5.1 shows the distribution of feeding method for each month and for all 4 
months combined.  Among infants not exclusively breastfed, the proportion of infants fed 
primarily a formula with DHA and AA added decreased from 72.4% in the first postnatal 
month to 61.2% in the fourth month (Table 5.1).  Eight infants were fed more than one 
formula product in one or more months.  Only 3 infants were fed only formulas with no 
DHA and AA added for all 4 months.  A few women (n=6) were unable to provide 
enough information about the formula they fed in one or more months to determine 
whether DHA and AA were added, and they were excluded from the combined models.  
The percent of fatty acids in the formulas ranged from 0.30 to 0.37% for DHA and 0.50 
to 0.67% for AA. 
Feedings of other foods like cereal, fruit, juice or other milk substitutes (i.e., 
cow’s milk) were not commonly seen in this cohort until infants were 3 months old.  At 
that time the most commonly eaten foods were cereal (14% of infants fed cereal one or 
more times per day), fruit or vegetables (4%), and juice (4%). 
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Table 5.2 presents characteristics of infants and mothers in the study in relation to 
the concentration of DHA and AA in breast milk, feeding method, and Mullen Composite 
scores.  Women with more years of education (t=-2.5, p=0.02) or a term infant (t=-2.5, 
p=0.02) had higher breast milk DHA levels on average than women with less education 
or an infant born preterm.  Mean DHA and AA concentration also differed by laboratory 
(for DHA: t=-6.3, p<0.01; for AA: t=-6.3, p<0.01).  Women who were white, non-
Hispanic, more highly educated, did not smoke, or had an infant at term tended to 
breastfeed more than women of another race and ethnicity, women with less education, 
smokers or women with preterm infants. 
.  The infants had mean Mullen t-scores and Composite scores similar to expected 
scores for a general population sample of infants, with mean sub-scale t-scores around 50 
and a mean Composite score of 99.  Women with more years of education and non-
smokers tended to have infants with higher Mullen Composite scores; female and term 
infants also tended to score higher.   
Only education, race and ethnicity, smoking and preterm status were found to be 
important confounders in the breastfeeding models.  In the unadjusted models, infants 
who were exclusively or almost exclusively breastfed for the first 4 months exhibited 
more advanced cognitive development compared to infants who were formula fed, but 
these differences were notably attenuated upon adjustment (Table 5.3).  Infants of women 
who discontinued breastfeeding before breast milk collection did not score lower on the 
Mullen Composite than infants of women who had a breast milk sample. 
The breast milk models included variables for lab batch, infant sex, parity, 
smoking, and preterm status as confounders.  Within the group of infants exclusively 
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breastfed for the first 4 months, there were no notable differences in Mullen sub-scale or 
Composite scores in relation to the concentration of DHA in breast milk (Table 5.4).  
Gross motor development was positively associated with AA concentration. 
In the combined models incorporating breast milk and formula DHA or AA 
concentrations and feeding method, there was no observed difference between infants in 
terms of Mullen sub-scale and Composite scores in relation to the weighted combination 
of DHA or AA in breast milk and formulas fed (Table 5.5).  Adjusted models included 
laboratory, feeding method for the 4 months combined, infant sex, parity, smoking, 
education, race/ethnicity, and preterm status as confounders. 
The results from the combined models were very similar when including imputed 
fatty acid values for women (n=88) who had no breast milk sample, so we report the 
estimates from complete case analyses. 
 
Discussion 
 Our goal was to address three questions about infant feeding and fatty acid 
exposure in relation to developmental outcomes at 12 months of age.  The breast feeding 
models addressed whether the extent of breastfeeding during the first 4 postnatal months 
is associated with cognitive development at 12 months.  Infants who were exclusively or 
almost exclusively breastfed for the first 4 months exhibited better cognitive development 
on several Mullen scales than formula fed infants but estimates were imprecise and 
attenuated after accounting for the role of maternal smoking, education, race and 
ethnicity and preterm birth.  These results are similar to some previous studies that found 
breastfeeding duration or exclusivity to be unrelated to infant development,128, 136 but in 
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contrast to other studies that noted enhanced development among breastfed infants.122, 135, 
139, 141, 142
  Studies vary in their ability to control for key confounders of the association 
between breastfeeding and infant development, and this may explain some of the 
variation in results.  Also, studies often use tests of global development which may not 
reveal whether specific aspects of development are affected differently from others.   
In models focused on breast milk, we found the LCPUFA concentration to be 
unrelated to infant development among exclusively breastfed infants.  Breast milk is the 
sole source of LCPUFAs for some infants through at least the first few months of life.  
The mean DHA and AA concentrations in the breast milk samples in this study were 
similar to those in other studies of U.S. women; for instance, Birch et al. found mean 
levels of 0.29% as DHA and 0.56% as AA.63  Studying the association between breast 
milk DHA and AA levels and developmental outcomes among children who were 
exclusively breastfed avoids the potential for confounding due to the choice of feeding 
method; this is a strength of the present study.  Most studies that focused on breast milk 
as the source of DHA have been maternal supplementation trials, and results have been 
equivocal possibly because global tests of development are generally used.144-146 
Because many infants are not exclusively breastfed, we built models that 
combined information about the DHA and AA concentration of breast milk samples and 
the DHA and AA concentration of formulas fed.  The relative DHA and AA contribution 
from each source was accounted for by weighting both concentrations by the feeding 
method for each month.  We are aware of no previous studies that incorporated 
information about changing feeding methods across time with measures of LCPUFA 
exposure from multiple sources.  This method of assessing exposure may better reflect 
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the reality of infant feeding, where feeding methods and formula choices change over 
time.  The results of these combined models showed no association between the 
constructed LCPUFA variables and developmental outcomes. 
 Several potential weaknesses underlie our findings.  First, we had too few infants 
fed only formulas without DHA and AA to be able to compare them to infants fed only 
formulas with DHA and AA.  When these data were collected, commercial formulas with 
DHA and AA added already comprised a substantial proportion of the formulas on the 
market.  Second, our method of assessing LCPUFA exposure by combining breast milk 
and formula sources is novel.  It treats LCPUFAs from breast milk and from formula as 
equally available to the infant; it is possible that the physiologic benefit to infants from 
LCPUFAs varies by source.  The method assumes the concentration of DHA and AA in 
breast milk is constant across lactation which is supported by recent studies, but may not 
be true for all women.80, 81  While our infant feeding interview was very detailed, it could 
not quantify amount consumed.   
Some infants were fed foods other than breast milk or formula one or more times 
per day by the time they reached 4 months of age.  These foods could be an additional 
source of LCPUFAs.  Typical baby foods are not a significant source of DHA (baby 
foods with DHA added were not commercially available during the time of this study), 
unless mixed with breast milk or formula.  Feeding baby foods could reduce overall 
LCPUFA exposure since the foods can displace breast milk and formula in the diet.  It 
was not possible with the available data to assess LCPUFA exposure from baby foods. 
Finally, because some women stopped breastfeeding before the study visit or 
refused to provide a breast milk sample, we were unable to directly measure their infants’ 
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exposure via breast milk and so they were excluded from the combined models.  We 
imputed breast milk DHA and AA values to be able to include them in the models and 
explore whether results would be altered.  Results were virtually unchanged, so we opted 
to present results with these women excluded.  
This study has several strengths; the first is generalizability.  Much of the research 
on the potential benefits of LCPUFAs has adopted a randomized design at least in part to 
eliminate issues of confounding.  Many of these studies tested formulas that were 
developed specially for research purposes and not for wide consumption.  Parents who 
were compliant with the study protocols would have fed their infants exclusively the 
assigned formula product and not breast milk or other formulas.  It is unclear whether the 
experience of the infants who participated in these studies is representative of formula-
fed infants in the general population who are fed commercially available formulas.  Also, 
many infants in the general population are fed some breast milk and some formula, and 
their experience is generally not reflected in these studies.   
Second, we incorporated LCPUFA content from breast milk and formula with 
detailed, monthly information about feeding method.  Most studies do not take into 
account the wide variation in the extent to which infants are breastfed or formula fed and 
the differences in LCPUFA content.  Previous studies have not had the benefit of this 
detailed information to examine dose-response relationships.  Also, we were able to 
include infants fed (for one to three months) formulas with no DHA or AA added.  This 
increased the variability of exposure compared to what might be observed in a sample of 
infants born more recently because almost all formula products today contain DHA and 
AA.  Most randomized studies employed intent-to-treat analysis.  This is normally a 
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strength, but it may obscure variations in exposure that occur.15, 112  For instance, many 
infants in the general population are exposed to LCPUFAs from both breast milk and 
formula.  Measuring exposure based on the actual breast feeding patterns and 
combinations of breast milk and formulas infants are fed would be more applicable to the 
general population.  A major strength of a randomized design is control of confounding 
factors.  However, this advantage may not outweigh the disadvantage of the lack of 
generalizability; a non-randomized design with a closer-to-representative sample and 
good control of confounding factors might be more informative in this case.  
Third, this study was able to account for several factors (e.g., education, smoking) 
that confound the association between feeding method and infant development.  Studies 
that compare breastfed children to formula-fed children are subject to criticism because 
of inadequate control of important confounding variables.  Because it is considered 
unethical to randomize infants to breastfeeding versus formula feeding, most randomized 
studies only randomize within the formula fed group (to a LCPUFA formula or a control 
formula).  The breastfed group is generally made up of infants who mothers intend to 
breastfeed while the formula-fed groups are infants whose mothers intend to formula 
feed.104, 116  Thus, those studies are subject to some of the same confounding issues as 
observational studies. 
Finally, few studies simultaneously assessed multiple aspects of infant 
development, not just global development, in relation to feeding method or LCPUFA 
exposure.  The Mullen offers sub-scales corresponding to specific developmental areas, 
exhibits high test-retest reliability, and correlates strongly with the Bayley MDI.217  To 
our knowledge, the Mullen has not previously been used to examine the associations 
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between feeding method or LCPUFA exposure and infant development.  This study 
employed trained interviewers who used standard assessment techniques with high 
reliability.   
 
Conclusion 
 The results of our analysis suggest that differences in visual reception, 
language, and motor skills, and overall cognitive development among infants at 12 
months may be explained by factors other than DHA and AA exposure, breastfeeding 
duration and exclusivity, and the socio-demographic factors that underlie choices 
about feeding method.  It is possible that the effects of LCPUFA intake are limited to 
visual acuity and are transient, or that more lasting effects do not become apparent 
until after infancy.  Continued efforts to improve LCPUFA exposure assessment in 
population-based studies may clarify possible associations. 
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Table 5.1.  Infant feeding characteristics in the PIN Babies Study, 2002-2006 
 1st postnatal 
month (n, %) 
2nd postnatal 
month 
3rd postnatal 
month 
4th postnatal 
month 
First 4 months 
combined 
Feeding methoda      
Exclusively or almost exclusively breastfed 266 (74.3) 251 (70.1) 229 (64.0) 215 (60.1) 207 (57.8) 
Partially breastfed 53 (14.8) 36 (10.1) 41 (11.5) 40 (11.2) 112 (31.3) 
Formula fed 39 (10.9) 71 (19.8) 88 (24.6) 103 (28.8) 39 (10.9) 
Primary formula fed (for those not exclusively breastfed)      
DHA, AA added 79 (72.4) 85 (68.0) 92 (63.4) 101 (61.2) -- 
No DHA, AA added 24 (22.0) 34 (27.2) 49 (33.8) 61 (37.0) -- 
unknown 6 (5.5) 6 (4.8) 4 (2.8) 3 (1.8) -- 
a
 Infants who were breastfed for all feedings per day for the first 4 postnatal months were considered exclusively breastfed.  Infants who were breastfed plus up to 
1 formula feeding per day were considered almost exclusively breastfed.  Infants who were fed infant formula for all daily feedings were considered formula fed.  
All other infants were partially breastfed. 
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Table 5.2.  Characteristics of Infants in the PIN Babies Study and Associations with Breast Milk DHA and AA Concentrations, Feeding Method, and 
Mullen Scales of Early Learning Composite Score, 2002-2006 
 Mean DHA 
concentration of 
breast milk (% of 
total fatty acids) 
(SD) 
Mean AA 
concentration of 
breast milk (% of 
total fatty acids) 
(SD) 
Feeding method (first 4 postnatal months)a Mullen 
Composite 
(mean, SD) 
   Exclusively or almost 
exclusively breastfed  
(n, %) 
Partially 
breastfed  
(n,%) 
Formula fed 
(n,%) 
 
Overall 0.28 (0.22) 0.57 (0.20) 207 (57.8) 112 (31.3) 39 (10.9) 99.4 (13.6) 
Race and ethnicity       
White, non-Hispanic 0.28 (0.23) 0.56 (0.18) 184 (65.0) 77 (27.2) 22 (7.8) 100.1 (13.6) 
All others 0.25 (0.17) 0.60 (0.30) 23 (30.7) 35 (46.7) 17 (22.7) 97.1 (13.8) 
Maternal education       
High school or less 0.20 (0.10) 0.50 (0.19) 7 (14.0) 29 (58.0) 14 (28.0) 95.7 (14.7) 
Greater than high school 0.28 (0.22) 0.57 (0.20) 200 (64.9) 83 (27.0) 25 (8.1) 100.1 (13.4) 
Preterm birth       
Preterm 0.21 (0.11) 0.56 (0.17) 14 (31.1) 22 (48.9) 9 (20.0) 94.1 (14.8) 
Term 0.28 (0.23) 0.57 (0.21) 193 (61.7) 90 (28.8) 30 (9.6) 100.2 (13.3) 
Smoking       
Yes 0.38 (0.28) 0.57 (0.19) 10 (22.7) 23 (52.3) 11 (25.0) 94.3 (12.6) 
No 0.27 (0.22) 0.57 (0.20) 197 (62.7) 89 (28.3) 28 (8.9) 100.1 (13.6) 
Parity       
0 0.30 (0.24) 0.58 (0.22) 104 (60.5) 55 (32.0) 13 (7.6) 99.6 (13.9) 
>=1 0.25 (0.20) 0.55 (0.18) 103 (55.4) 57 (30.7) 26 (14.0) 99.3 (13.4) 
Infant sex       
Female 0.30 (0.23) 0.58 (0.22) 94 (57.3) 54 (32.9) 16 (9.8) 102.3 (14.0) 
Male 0.26 (0.21) 0.55 (0.18) 113 (58.6) 57 (29.5) 23 (11.9) 97.1 (12.8) 
Laboratory       
Minnesota 0.20 (0.15) 0.50 (0.10) 109 (85.2) 19 (14.8) -- 100.6 (14.2) 
North Carolina 0.37 (0.26) 0.65 (0.26) 86 (83.5) 17 (16.5) -- 101.7 (13.0) 
a
 Infants who were breastfed for all feedings per day for the first 4 postnatal months were considered exclusively breastfed.  Infants who were breastfed plus up to 
1 formula feeding per day were considered almost exclusively breastfed.  Infants who were fed infant formula for all daily feedings were considered formula fed.  
All other infants were partially breastfed. 
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Table 5.3.  Association between feeding method for the first four postnatal months and scores on the Mullen Scales of Early Learning, PIN Babies 
study, 2002-2006 
Mullen Scales of Early Learning  Feeding Method (formula fed=reference, n=39) 
  Exclusively or almost exclusively breastfed (n=207) Partially Breastfed (n=112) 
Gross motor    
 β (CI) (unadjusted model) 1.7 (-2.4, 5.8) 0.9 (-3.5, 5.3) 
 β (CI) (adjusted model) b 1.1 (-3.4, 5.5) 0.8 (-3.6, 5.2) 
Visual reception    
 β (CI) (unadjusted model) 4.4 (0.7, 8.2) 0.6 (-3.4, 4.7) 
 β (CI) (adjusted model) b 2.5 (-1.6, 6.6) 0.0 (-4.1, 4.0) 
Fine motor    
 β (CI) (unadjusted model) 4.6 (0.8, 8.3) 2.2 (-1.8, 6.3) 
 β (CI) (adjusted model) b 2.7 (-1.4, 6.8) 1.5 (-2.6, 5.6) 
Receptive language    
 β (CI) (unadjusted model) 1.2 (-1.6, 3.9) -1.2 (-4.1, 1.7) 
 β (CI) (adjusted model) b 0.7 (-2.3, 3.7) -1.3 (-4.2, 1.7) 
Expressive language    
 β (CI) (unadjusted model) 2.2 (-0.9, 5.3) 0.4 (-2.9, 3.7) 
 β (CI) (adjusted model) b 1.7 (-1.7, 5.1) 0.3 (-3.1, 3.6) 
Composite    
 β (CI) (unadjusted model) 6.2 (1.6, 10.8) 1.0 (-4.0, 5.9) 
 β (CI) (adjusted model) b 4.0 (-1.1, 9.0) 0.2 (-4.8, 5.2) 
a
 Infants who were breastfed for all feedings per day for the first 4 postnatal months were considered exclusively breastfed.  Infants who were breastfed plus up to 
1 formula feeding per day were considered almost exclusively breastfed.  Infants who were fed infant formula for all daily feedings were considered formula fed.  
All other infants were partially breastfed. 
b
 Adjusted models include education, race and ethnicity, smoking, and preterm status. 
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Table 5.4.  Association between DHA, AA in breast milk and scores on the Mullen Scales of Early Learning among infants exclusively breastfed (n=183) 
the first 4 postnatal months, PIN Babies Study, 2002-2006 
  Breast milk DHA (continuous) Breast milk AA (continuous) 
Mullen Scales of Early Learning    
Gross motor    
 β (CI) (unadjusted model) a 5.6 (-2.8, 13.9) 10.6 (0.5, 20.7) 
 β (CI) (adjusted model) b 3.9 (-4.6, 12.4) 9.0 (-1.0, 19.0) 
Visual reception    
 β (CI) (unadjusted model) a -3.5 (-11.1, 4.1) 4.3 (-4.7, 13.3) 
 β (CI) (adjusted model) b -2.7 (-10.5, 5.1) 4.4 (-4.6, 13.3) 
Fine motor    
 β (CI) (unadjusted model) a 2.8 (-4.8, 10.5) 3.8 (-5.3, 12.8) 
 β (CI) (adjusted model) b 2.3 (-5.2, 9.9) 1.7 (-7.0, 10.4) 
Receptive language    
 β (CI) (unadjusted model) a 0.7 (-4.5, 5.9) 3.5 (-2.8, 9.8) 
 β (CI) (adjusted model) b -0.7 (-5.9, 4.5) 2.2 (-4.0, 8.5) 
Expressive language    
 β (CI) (unadjusted model) a -0.4 (-6.3, 5.6) 4.7 (-2.4, 11.9) 
 β (CI) (adjusted model) b -1.6 (-7.6, 4.4) 3.6 (-3.6, 10.8) 
Composite    
 β (CI) (unadjusted model) a -0.3 (-9.5, 8.8) 8.2 (-2.6, 19.1) 
 β (CI) (adjusted model) b -1.3 (-10.3, 7.7) 6.1 (-4.3, 16.5) 
aUnadjusted models include a variable for laboratory 
bAdjusted models include lab batch, infant sex, parity, smoking, and preterm status
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Table 5.5.  Association between DHA, AA in breast milk and infant formula weighted by feeding method for the first four postnatal months and scores 
on the Mullen Scales of Early Learning, PIN Babies Study, 2002-2006 
  DHA in breast milk and formula 
(continuous) 
AA in breast milk and formula 
(continuous) 
Mullen Scales of Early Learning    
Gross motor    
 β (CI) (unadjusted model) a 1.3 (-0.7, 3.2) 1.4 (-0.9, 3.6) 
 β (CI) (adjusted model) b 1.1 (-0.9, 3.1) 1.2 (-1.1, 3.4) 
Visual reception    
 β (CI) (unadjusted model) a -0.2 (-2.0, 1.7) 0.8 (-1.3, 2.8) 
 β (CI) (adjusted model) b -0.1 (-2.0, 1.8) 0.7 (-1.3, 2.8) 
Fine motor    
 β (CI) (unadjusted model) a 0.5 (-1.4, 2.3) 0.3 (-1.7, 2.4) 
 β (CI) (adjusted model) b 0.2 (-1.7, 2.0) 0.0 (-2.0, 2.0) 
Receptive language    
 β (CI) (unadjusted model) a 0.3 (-1.0, 1.5) 0.4 (-1.0, 1.9) 
 β (CI) (adjusted model) b -0.1 (-1.4, 1.2) 0.3 (-1.2, 1.7) 
Expressive language    
 β (CI) (unadjusted model) a -0.2 (-1.6, 1.2) 1.0 (-0.6, 2.7) 
 β (CI) (adjusted model) b -0.6 (-2.1, 0.8) 0.7 (-0.9, 2.3) 
Composite    
 β (CI) (unadjusted model) a -0.0 (-2.3, 2.2) 1.2 (-1.3, 3.7) 
 β (CI) (adjusted model) b -0.5 (-2.7, 1.7) 0.9 (-1.5, 3.4) 
aUnadjusted models include a variable for laboratory 
bAdjusted models include laboratory, feeding method for first 4 postnatal months, infant sex, parity, smoking, education, race/ethnicity, and preterm status
  
 
CHAPTER 6 
RESULTS 
Specific Aim 2: A prospective study of maternal anxiety, perceived stress, and 
depressive symptoms in relation to infant cognitive development 
 
Introduction 
Infancy is a period of rapid cognitive development, transitioning between the critical 
early brain development in utero and the emergence of more advanced abilities in later 
childhood.  The early psychosocial environment of the child plays a role in mental and 
emotional health across the lifespan.  Maternal anxiety, stress, and depression are common 
psychosocial influences of concern for child development.  Pregnancy and new motherhood 
may be particularly stressful periods for women; with postpartum depression affecting up to 
19% of new mothers.23 
Anxiety, stress, and depressive symptoms are inter-related phenomena; women who 
perceive their circumstances as highly stressful are also likely to experience more depressive 
symptoms or anxiety.25  Mothers who experience significant anxiety, stress, or depression 
may provide a less stimulating environment for their children’s development at least in part 
because they may react inappropriately to their children’s cues.184, 245, 246  Numerous studies 
have observed an association between maternal postpartum or chronic depressive symptoms 
and poorer child performance on cognitive and behavioral assessments.26-35  Studies noted 
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that greater maternal stress and anxiety interfere with mother-child interaction, with 
consequences for infant temperament and cognition.36-39  However, few studies have reported 
negative effects as early as infancy, and those results have been inconsistent.29, 40, 41  
Variability across studies could be due to variation in the timing and methods of assessing 
maternal psychological health, the timing and challenges of assessing very young children, 
insufficient statistical power to detect small effects, and varying ability to control for key 
confounders.  Additionally, previous studies have used a variety of instruments to assess 
child development, often assessing development globally.  Some areas of development may 
be more affected by maternal affect than others; thus separately evaluating language, visual 
reception, and motor skills provide more detail about potential associations. 
 This study examines maternal trait anxiety, perceived stress, and depressive 
symptoms during the pre- and early post-natal period in relation to infant visual reception, 
language, and motor skills, and overall cognitive development as measured via the Mullen 
Scales of Early Learning (the Mullen).   
 
Methods 
Study population 
The Data were collected as part of the Pregnancy, Infection, and Nutrition Study 
(PIN) and its postnatal follow-up components, PIN Postpartum and PIN Babies.  The 
goal of the PIN Study is to identify factors associated with preterm birth.  The goal of 
PIN Postpartum is to identify modifiable behaviors associated with high gestational 
weight gain and postpartum weight retention.45  PIN Babies focuses on child 
developmental outcomes in relation to the prenatal and early childhood environment.  
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The University of North Carolina Biomedical Institutional Review Board approved all 
protocols; all participants provided informed consent.   
 Women (n=1,169) were eligible for PIN Postpartum if they completed the third 
wave of the PIN Study, agreed to be contacted after delivery, and did not become 
pregnant again in the first year postpartum.  Medical constraints (n=24), inability to 
recontact (n=207) or schedule (n=62), and refusal (n=187) resulted in 689 women who 
participated in a visit scheduled in the fourth postpartum month.  Of these, 45 became 
pregnant again, 62 were unreachable, 29 moved from the study area, and 20 left the study 
before the PIN Babies visit at 12 months could be scheduled.  The PIN Babies protocol 
began after PIN Postpartum began, and 125 infants were ineligible to complete the 
protocol because they reached 12 months of age before the study began conducting the 
assessments in the home.  Among the remaining 408 eligible maternal-infant pairs, some 
did not participate in the Mullen because the child was not present (n=11, e.g. the mother 
completed the interview from work); the child was asleep, sick, or fussy (n=21); the 
mother refused the child’s participation (n=8); there was not enough time during the visit 
(n=3); or other reasons (n= 7). 
 
Data collection 
 During pregnancy, information about depressive symptoms was collected via self-
administered questionnaires before 20 weeks gestation and at 24-29 weeks gestation 
using the Centers for Epidemiologic Studies Depression (CES-D) scale.212  The CES-D is 
intended to measure depressive symptoms in general population samples.  The 
questionnaire before 20 weeks gestation included the State-Trait Anxiety Inventory 
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(STAI), the Rosenberg Self-Esteem Scale, and the MOS Social Support scale.193, 213, 214  
The trait score of the STAI is a measure of an individual’s general feelings of anxiety and 
is relatively stable over time, in contrast to state anxiety which is situational.193  Age, 
education, income and other demographic and lifestyle covariates were obtained via 
telephone at 17-22 weeks gestation.  Delivery information was obtained from the hospital 
record.  Preterm birth was defined as less than 37 completed weeks gestation at delivery, 
based on ultrasound if done before 20 weeks gestation or the date of the last menstrual 
period. 
The home visit in the fourth postpartum month collected information on maternal 
and infant health and nutrition and updated information about family circumstances and 
maternal psychosocial health.  The interview included the Edinburgh Postnatal 
Depression Scale (EPDS), a screening tool for depressive symptoms, and the 10-item 
Perceived Stress Scale to measure the extent to which one’s circumstances are perceived 
as stressful.215, 216 
At 12 months postpartum, study staff administered the Mullen following 
procedures outlined in the Mullen manual.  The Mullen is a commonly used assessment 
of cognitive functioning appropriate for children up to 68 months of age.  Five sub-scales 
separately assess visual reception, expressive and receptive language, and fine and gross 
motor development.  All but gross motor are combined to comprise a composite score 
reflecting overall cognitive ability. 
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Statistical analysis 
Continuous scores from the trait anxiety scale of the STAI and the Perceived 
Stress Scale were categorized into tertiles based on their observed distribution in the 
study participants.  A variable was constructed to examine depressive symptoms across 
both the antepartum and postpartum periods based on scores on the CES-D and EPDS.  
Women were classified as having few depressive symptoms postpartum (EPDS=0-9) 
(regardless of antepartum symptoms), minor or major depressive symptoms only during 
the postpartum period (EPDS > 9 and both CES-D scores=0-16), and minor or major 
depressive symptoms during both the postpartum and antepartum periods (EPDS > 9 and 
at least one CES-D score > 16).  The 9/10 cutpoint for the EPDS has been validated in 
previous studies to measure minor depression or increase the sensitivity of the instrument 
to depression, and it has been shown to identify cases of clinical depression with more 
than 90% sensitivity.228-231  The 16/17 cutpoint for the CES-D was chosen because 
several studies have reported reduced specificity of the CES-D using the 15/16 cutpoint 
for pregnant women because some symptoms of pregnancy (e.g., fatigue) are similar to 
CES-D components.225-227 
Raw scores were converted to age-specific t-scores for the four cognitive sub-
scales (Visual Reception, Fine Motor, Receptive Language, Expressive Language) and 
the Gross Motor sub-scale of the Mullen.  The cognitive t-scores were summed and 
converted to a standard Early Learning Composite (Composite) score following 
procedures outlined in the manual.217 
All analyses adjusted for preterm status; however scores were not directly 
adjusted for gestational age at birth because we found the procedure recommended in the 
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manual potentially overcorrected scores for preterm infants.  The age-adjusted mean 
score for preterm infants was higher than the mean score for term infants for the 
Composite and all of the Mullen sub-scales except the Fine Motor scale, although the 
difference was statistically significant for the Receptive Language sub-scale only (age-
adjusted mean Receptive Language t-score for preterm infants=48.9, term infants=45.9, 
t=2.3, p=0.02). 
Linear regression models were used to examine the association between maternal 
anxiety, perceived stress, or depressive symptoms and infant scores on each Mullen sub-scale 
and the Composite.  The residuals were found to be approximately normally distributed using 
kernel density and Q-Q plots and to have constant variance using the White test and plots of 
the residuals versus predicted values.244  Observations were considered to be independent 
because only one child per family participated.  The exposure-outcome relationships 
appeared to be linear.  Since the exposure categories have an inherent ordering, tests for 
linear trend for each unadjusted model were conducted by including in a regression model a 
continuous variable for the median value of the anxiety or stress score for each tertile of 
anxiety or stress.  To assess a linear trend for the depressive symptoms models, linear 
regression models included a categorical three-level depressive symptoms variable.   
Multiple partial F-tests checked for effect measure modification by poverty, maternal 
pre-pregnancy body mass index (BMI), education, social support, infant sex, preterm birth, 
presence of a spouse/partner, and one or more of trait anxiety, depressive symptoms, and 
perceived stress depending on the exposure of interest.  Potential confounders were identified 
a priori based on previous studies and constructed Directed Acyclic Graphs.234, 235  Poverty, 
maternal pre-pregnancy BMI, social support, infant sex, and presence of a spouse/partner 
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were considered potential confounders a priori but were eliminated via the change-in-
estimate approach.247  This produced a final set of covariates that resulted in a change of 
greater than 10% in the beta coefficient for the exposure variable when removed from a 
model.247  Adjusted models incorporated confounders based on this selection process. 
To include women with missing data on anxiety (5.1% of women), covariates, or 
depressive symptoms at 1 or 2 time points (15.8% missing 1 time point, 3.4% missing 2 time 
points), multiple imputation was used to impute missing data .  The Markov chain Monte 
Carlo method using SAS procedure (PROC MI) produced 10 replications of the dataset with 
missing values imputed.236-238  The imputation model included: CES-D scores during 
pregnancy, EPDS score, perceived stress scores (17-22 weeks gestation,  27-30 weeks 
gestation, fourth month postpartum), trait anxiety score, state anxiety score at less than 20 
weeks gestation, Rosenberg self-esteem score, MOS social support score, maternal age, 
family income as a percentage of the federal poverty level, maternal pre-pregnancy BMI, 
education, gestational age at delivery, parity, maternal race, infant sex, each Mullen sub-scale 
score and Composite score, and infant scores on the MacArthur Communicative 
Development Inventory at 12 months.248  (For the purposes of this publication, we focused on 
the Mullen; MacArthur scores were not analyzed.)  The imputed datasets were analyzed 
using SAS (version 9.1) linear regression procedures and combined with PROC 
MIANALYZE to produce the effect estimates reported.238  
 
Results 
To be eligible for this analysis, infants must have completed at least one sub-scale of 
the Mullen (n=358; 343 completed all).  Table 6.1 shows trait anxiety, depressive symptoms, 
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and perceived stress categories in relation to participant characteristics.  Approximately 10% 
of women experienced minor or major depressive symptoms during both the ante- and 
postpartum periods.  Higher levels of anxiety, stress, and depressive symptoms were 
associated with younger maternal age, low self-esteem, poverty, and fewer years of 
education, but not with preterm birth.  Anxiety, stress, and depressive symptoms were 
positively correlated with each other (Spearman 
∧
ρ  for anxiety and stress=0.41 (p=0.04), for 
anxiety and depressive symptoms=0.30 (p=0.04), for stress and depressive symptoms=0.51 
(p=0.03)). 
Infants had mean Mullen t-scores and Composite scores similar to expected for a 
general population sample of infants, with mean sub-scale t-scores around 50 and a mean 
Composite score of 99 (Table 6.1).  Older and more educated mothers tended to have infants 
with higher Fine Motor scores (data not shown).  Infants of women with more education also 
tended to score higher on the Composite.  Preterm infants had lower Gross Motor, Fine 
Motor, and Composite scores than term infants. 
Maternal anxiety was inversely associated with Receptive Language t-scores; infants 
of mothers in the highest anxiety group scored slightly lower than those in the lowest group, 
in a model adjusted for preterm birth, education, and self-esteem (Table 6.2).  Anxiety was 
also associated with lower Composite scores.  Trend tests suggested a linear trend across 
categories of anxiety for Receptive Language and Composite scores; increasing levels of 
anxiety were associated with decreasing Mullen scores, although all estimates were 
imprecise. 
Maternal antepartum and postpartum depressive symptoms were not associated with 
Mullen scores (Table 6.3).  The results were similar for maternal perceived stress, with the 
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exception of a positive association with Receptive Language scores.  No effect measure 
modification was detected for the associations evaluated in Tables 6.2-6.4. 
To address the possibility that women in PIN who refused or who were unable to 
participate in the study through the 12-month visit might be more likely to have significant 
levels of anxiety, stress and depressive symptoms and an infant who would have scored 
poorly on the Mullen, we examined the available antepartum anxiety, stress and depressive 
symptoms data.  Women who were eligible but refused, were unreachable or not able to be 
scheduled for a visit in the fourth postpartum month were more likely to score above 16 on 
the CES-D at either time point and to score in the highest trait anxiety tertile (OR for CES-D 
17+=1.5, 95% CI: 1.1, 2.0; OR for highest anxiety tertile=1.4, 95% CI: 1.1, 1.8) compared to 
women who participated in the first postpartum visit.  Those who participated in the first 
postpartum visit but not the second visit at 12 months were more likely to score in the highest 
perceived stress tertile than those who participated in both visits (OR for the highest 
tertile=1.7, 95% CI: 1.1, 2.5), but scored no differently on the EPDS or trait anxiety scales 
(OR for EPDS 10+=1.2, 95% CI: 0.7, 1.9; OR for highest anxiety tertile=1.0, 95% CI: 0.6, 
1.5).  It is not possible to determine with available data whether the children who 
discontinued participation would have had lower Mullen scores.  However, we examined 
other infant characteristics that might be related to Mullen scores.  Infants who were born 
preterm were as likely as term infants to participate in the home visits ( 21χ  for the first 
visit=0.18, p=0.67; 21χ
 for the second visit=0.20, p=0.66).  Maternal anxiety, stress, or 
depressive symptoms were no more strongly associated with an infant being preterm among 
those who stopped participation after the first home visit compared to those who completed 
the second visit. 
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Discussion 
Elevated maternal trait anxiety was found to be associated with lower Receptive 
Language and Composite scores in adjusted models.  Receptive language reflects the infant’s 
use of both visual and auditory skills to process information.  It is possible that mothers with 
high anxiety levels participate in fewer language stimulation activities with their infants, or it 
could be that unmeasured factors underlying maternal anxiety could affect receptive 
language ability as well.  Previous research has found anxious mothers to be less likely to 
speak to their infants and less sensitive and responsive to their needs.249,250  The association 
between maternal anxiety and Composite scores suggests anxiety may exert a slight negative 
effect across several areas of motor and language development, if not only through receptive 
language. 
The observed difference between infants exposed to the highest levels of maternal 
anxiety and those exposed to the lowest levels was small (approximately one-third of a 
standard deviation) and imprecise.  In comparison, a study comparing “late-talking” toddlers 
to normally developing toddlers observed a 9.5 point difference.251  However, even small 
differences within the normal range can be meaningful at the population level.252 
High levels of perceived stress were associated with slightly higher Receptive 
Language t-scores.  This is unexpected in light of previous studies that assessed maternal 
stress in relation to infant behavior and global development.253, 254  There were no significant 
differences in other Mullen sub-scale or Composite scores between infants exposed to 
maternal trait anxiety, postpartum stress, or antepartum and postpartum depressive symptoms 
after adjusting for key confounders. 
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Several factors may have contributed to the null results observed here.  First, many 
women in this study were well-educated, had adequate financial resources, and reported high 
levels of social support.  These factors may buffer the child’s development from detrimental 
effects of depressive symptoms or stressful circumstances.   
Second, women who experienced significant depressive symptoms or anxiety during 
pregnancy or high stress levels postpartum were somewhat less likely to participate 
postpartum.  If these children would also have scored lower on the Mullen scales than 
participating children, these results may underestimate the true association, but the data to 
evaluate this were unavailable. 
Third, stress, anxiety, and depression can occur together and be easily confounded by 
each other and other demographic factors.  This study was able to examine the role of several 
factors that may affect the observed associations between maternal anxiety, stress, and 
depressive symptoms and infant development.  The lack of control for key demographic and 
psychosocial confounders could have contributed to spurious or exaggerated associations 
between depressive symptoms and infant development in previous studies. 
Finally, most previous studies reporting detrimental effects of maternal anxiety, stress 
or depression were focused on older children.  Our finding that anxiety was associated with 
poorer receptive language among infants is one of a few published studies to observe 
differences in infants.  It is possible that additional effects of these exposures might become 
apparent when the children are older. 
This sample of infants was larger and more population-based than many previous 
clinical samples, which may have enabled us to detect subtle differences between groups.  
However, because the infants were generally developing typically, differences among them 
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due to maternal psychosocial characteristics may be slight and difficult to detect, and may 
partially account for null results.  Also, we used a standard but lower threshold for the EPDS 
to enhance the sensitivity for a broader group of women who may have had minor depression 
in the postpartum period.215  This inclusiveness may explain our inability to observe an 
association between depressive symptoms and infant development because maternal stress, 
depression, and anxiety may only adversely affect infant development when it is severe.  We 
examined results using a cutpoint of 12/13 for the EPDS, and most parameter estimates were 
larger than our reported results but very imprecise.  A larger sample of participants would 
enable detection of differences with greater precision. 
The multiple imputation techniques assume that the missing data can be predicted 
from the available data; however, no statistical test can verify this.236  The wide range of 
demographic and psychosocial variables in this dataset that were used to impute missing 
values provides some assurance that missingness was reasonably predicted, and imputation 
produced slightly more precise results than complete case analyses. 
Several strengths distinguish this study.  First, few studies have simultaneously 
assessed multiple aspects of infant development, not just global development, in relation to 
these exposures.  The Mullen offers sub-scales corresponding to specific developmental 
areas, exhibits high test-retest reliability, and correlates strongly with the Bayley MDI.217  
The Mullen has not previously been used to examine the associations between maternal 
anxiety, stress and depressive symptoms and child development in a sample of typically 
developing infants.  Some previous studies relied on maternal report for measures of infant 
outcomes which can inflate the association between poor maternal psychological health and 
infant behavior since depressed mothers may be more critical or less observant of their 
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child’s development.  This study employed trained interviewers who used standard 
assessment techniques with high reliability.  This study also relied on well-established, 
validated instruments for measuring anxiety, stress, and depressive symptoms.  The CES-D, 
EPDS, STAI, and Perceived Stress scales are commonly used instruments in psychosocial 
research and have been applied in many studies of pregnancy or postpartum health.37, 40, 187, 
226, 255
  Finally, the longitudinal design of this study allowed assessment of maternal 
psychological health in the antepartum and postpartum periods before the developmental 
outcomes were assessed at 12 months.  This avoided assessing the exposures based on recall 
or confusing the temporal sequence of the exposures and outcomes. 
 
Conclusion 
Infants of mothers with elevated levels of trait anxiety exhibited slightly lower 
receptive language and overall cognitive ability compared to infants of mothers with low 
levels of trait anxiety, after adjusting for preterm birth, maternal education, and self-esteem.  
No similar associations were observed for infants exposed to maternal minor or major 
depressive symptoms or to perceived stress.  The effects of maternal psychological disorders 
might be more likely to produce subtle shifts in development rather than developmental 
delays.  Continued efforts to follow this cohort for future language and general cognitive 
development would be valuable to see if the associations with anxiety persist or if 
associations with maternal depressive symptoms or stress become apparent.  Clinicians 
should be aware of the potential detrimental effect of maternal anxiety on very early child 
development.
  
 99
 
Table 6.1. Characteristics of mothers and infants in the Pregnancy, Infection, and Nutrition (PIN), PIN Postpartum and PIN Babies 
Studies and associations with maternal depressive symptoms, trait anxiety, and perceived stress, 2002-2006 
 n (%) State-Trait Anxiety Inventory (trait 
anxiety score) 
Antepartum and postpartum depressive 
symptoms 
Cohen’s Perceived Stress 
Scale score 
Mullen 
Scales of 
Early 
Learning 
Composite 
      Few 
symptoms 
postpartum 
Minor or 
major 
depressive 
symptoms 
postpartum 
Minor or 
major 
symptoms 
postpartum 
and 
antepartum 
    
  Score = 
0-<31  
(n, %) 
31-<40 
 (n, %) 
40+ 
(n, %) 
Missing 
(n, %) 
EPDS 
score=0-9 
(n, %) 
EPDS score 
10+ and 
both CES-D 
scores=0-16 
(n, %) 
EPDS score 
10+ and at 
least 1 CES-
D score= 
17+ (n, %) 
Score= 
0-<11 
(n, %)  
11-<17  
(n, %) 
17+ 
 (n, %) 
Mean, SD 
All 
women (n, 
%) 
358 
(100) 
118 
(33.0) 
127 
(35.5) 
91 
(25.4) 
22 (6.2) 302 (84.4) 21 (5.9) 35 (9.8) 120 
(33.5) 
150 
(41.9) 
88 
(24.6) 
99.4 
(13.6) 
Maternal 
age 
(years) 
            
17-20 16 (4.5) 1 (6.3) 4 (25.0) 9 
(56.3) 
2 (12.5) 8 (50.0) 1 (6.3) 7 (43.8) 2 (12.5) 5 (31.3) 9 (56.3) 96.7 
(17.2) 
21-30 167 
(46.6) 
45 
(27.0) 
55 
(32.9) 
54 
(32.3) 
13 (7.8) 139 (83.2) 9 (5.4) 19 (11.4) 57 
(34.1) 
66 
(39.5) 
44 
(26.4) 
98.8 
(13.5) 
31-47 175 
(48.9) 
72 
(41.1) 
68 
(38.9) 
28 
(16.0) 
7 (4.0) 155 (88.6) 11 (6.3) 9 (5.1) 61 
(34.9) 
79 
(45.1) 
35 
(20.0) 
100.3 
(13.4) 
Self-
esteem 
            
0-49 106 
(29.6) 
9 (8.5) 36 
(34.0) 
61 
(57.6) 
0 (0.0) 76 (71.7) 5 (4.7) 25 (23.6) 23 
(21.7) 
41 
(38.7) 
42 
(39.6) 
99.7 
(13.6) 
50-55 114 
(31.8) 
34 
(29.8) 
57 
(50.0) 
23 
(20.2) 
0 (0.0) 97 (85.1) 10 (8.8) 7 (6.1) 35 
(30.7) 
51 
(44.7) 
28 
(24.6) 
99.3 
(13.3) 
56-60 114 
(31.8) 
75 
(65.8) 
32 
(28.1) 
7 
(6.1) 
0 (0.0) 109 (95.6) 3 (2.6) 2 (1.8) 57 
(50.0) 
47 
(41.2) 
10 (8.8) 100.1 
(13.7) 
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missing 24 (6.7) 0 (0.0) 2 (8.3) 0 
(0.0) 
22 
(91.7) 
20 (83.3) 3 (12.5) 1 (4.2) 5 (20.8) 11 
(45.8) 
8 (33.3) 96.4 
(15.4) 
Poverty             
<185% of 
federal 
level 
49 
(13.7) 
3 (6.1) 14 
(28.6) 
23 
(46.9) 
9 (18.4) 32 (65.3) 5 (10.2) 12 (24.5) 10 
(20.4) 
18 
(36.7) 
21 
(42.9) 
96.7 
(15.0) 
185-350% 73 
(20.4) 
22 
(30.1) 
27 
(37.0) 
20 
(27.4) 
4 (5.5) 62 (84.9) 5 (6.9) 6 (8.2) 19 
(26.0) 
30 
(41.1) 
24 
(32.9) 
98.1 
(14.5) 
>350% 225 
(62.8) 
91 
(40.4) 
82 
(36.4) 
43 
(19.1) 
9 (4.0) 200 (88.9) 11 (4.9) 14 (6.2) 90 
(40.0) 
97 
(43.1) 
38 
(16.9) 
100.4 
(13.0) 
missing 11 (3.1) 2 (18.2) 4 (36.4) 5 
(45.5) 
0 (0.0) 8 (72.7) 0 (0.0) 3 (27.3) 1 (9.1) 5 (45.5) 5 (45.5) 101.3 
(12.3) 
Maternal 
education 
            
0-12 years 50 
(14.0) 
6 (12.0) 9 (18.0) 26 
(52.0) 
9 (18.0) 33 (66.0) 3 (6.0) 14 (28.0) 8 (16.0) 18 
(36.0) 
24 
(48.0) 
95.7 
(14.7) 
13-16 177 
(49.4) 
54 
(30.5) 
67 
(38.9) 
47 
(26.6) 
9 (5.1) 150 (84.8) 10 (5.7) 17 (9.6) 61 
(34.5) 
79 
(44.6) 
37 
(20.9) 
99.0 
(13.8) 
>16 131 
(36.6) 
58 
(44.3) 
51 
(38.9) 
18 
(13.7) 
4 (3.1) 119 (90.8) 8 (6.1) 4 (3.1) 51 
(38.9) 
53 
(40.5) 
27 
(20.6) 
101.5 
(12.7) 
Preterm 
birth 
            
Term 313 
(87.4) 
108 
(34.5) 
108 
(34.5) 
79 
(25.2) 
18 (5.8) 266 (85.0) 16 (5.1) 31 (9.9) 109 
(34.8) 
127 
(40.6) 
77 
(24.6) 
100.2 
(13.3) 
Preterm 45 
(12.6) 
10 
(22.2) 
19 
(42.2) 
12 
(26.7) 
4 (8.9) 36 (80.0) 5 (11.1) 4 (8.9) 11 
(24.4) 
23 
(51.1) 
11 
(24.4) 
94.1 
(14.8) 
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Table 6.2. Results of linear regression models for the association between maternal trait anxiety score and scores on the Mullen Scales of 
Early Learning: Pregnancy, Infection, and Nutrition (PIN), PIN Postpartum and PIN Babies Studies, 2002-2006 
 State-Trait Anxiety Inventory (trait anxiety score)  
 Score=0-<31 
(n=118, 35.1%) 
31-<40 
(n=127, 37.8%) 
40+ 
(n=91, 27.1%) 
P for trenda 
Mullen Scales of Early Learning     
Gross motor    0.60 
Mean (SD) 50.3 (12.4) 48.7 (12.3) 50.9 (10.8)  
β (95% CI) (Unadjusted model) - -1.5 (-4.5, 1.5) 0.6 (-2.6, 3.8)  
β (95% CI) (Adjusted model)b - -1.8 (-5.0, 1.4) 1.1 (-2.9, 5.1)  
Visual reception    0.10 
Mean (SD) 51.8 (11.1) 48.7 (11.4) 47.8 (10.0)  
β (95% CI) (Unadjusted model) - -3.0 (-5.8, -0.2) -4.0 (-6.9, 1.0)  
β (95% CI) (Adjusted model)b - -2.6 (-5.6, 0.3) -3.0 (-6.7, 0.6)  
Fine motor    0.50 
Mean (SD) 51.3 (11.3) 48.6 (11.0) 50.0 (10.9)  
β (95% CI) (Unadjusted model) - -2.7 (-5.5, 0.0) -1.3 (-4.4, 1.7)  
β (95% CI) (Adjusted model)b - -2.9 (-5.8, 0.1) -1.4 (-5.0, 2.2)  
Receptive Language    0.02 
Mean (SD) 46.8 (7.0) 45.4 (8.3) 44.8 (8.5)  
β (95% CI) (Unadjusted model) - -1.4 (-3.4, 0.6) -2.0 (-4.1, 0.1)  
β (95% CI) (Adjusted model)b - -1.8 (-4.0, 0.3) -2.9 (-5.6, -0.3)  
Expressive Language    0.53 
Mean (SD) 53.2 (9.0) 53.2 (9.0) 52.8 (8.9)  
β (95% CI) (Unadjusted model) - 0.0 (-2.2, 2.3) -0.4 (-2.8, 2.0)  
β (95% CI) (Adjusted model)b - -0.2 (-2.6, 2.2) -1.0 (-4.0, 2.1)  
Composite    0.05 
Mean (SD) 101.9 (13.5) 98.3 (13.6) 97.9 (13.3)  
β (95% CI) (Unadjusted model) - -3.5 (-6.9, -0.2) -4.0 (-7.6, -0.4)  
β (95% CI) (Adjusted model)b - -3.9 (-7.5, -0.3) -4.5 (-8.9, 0.0)  
aTrend tests are reported for the adjusted models 
bCovariates include preterm birth, maternal education, self-esteem  
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Table 6.3. Results of linear regression models for the association between maternal depressive symptoms and scores on the Mullen Scales 
of Early Learning: Pregnancy, Infection, and Nutrition (PIN), PIN Postpartum and PIN Babies Studies, 2002-2006 
 Antepartum and postpartum depressive symptoms  
 Few symptoms 
postpartum 
Minor or major depressive 
symptoms postpartum only 
Minor or major symptoms 
postpartum and antepartum 
 
 
Mullen Scales of Early Learning EPDS score=0-9 
(n=302, 84.4%) 
EPDS score 10+ & both CES-D 
scores=0-16 (n=21, 5.9%) 
EPDS score 10+ & at least one 
CES-D score=17+ (n=35, 9.8%) 
P for 
trenda 
Gross motor    0.50 
Mean (SD) 49.4 (11.9) 52.1 (15.1) 52.1 (11.3)  
β (95% CI) (Unadjusted model) - 2.6 (-4.0, 9.2) 2.7 (-1.5, 6.8)  
β (95% CI) (Adjusted model)b - 1.5 (-5.4, 8.5) 1.7 (-3.5, 6.9)  
Visual reception    0.61 
Mean (SD) 50.0 (11.2) 45.7 (10.3) 47.3 (9.9)  
β (95% CI) (Unadjusted model) - -4.3 (-9.9, 1.4) -2.7 (-6.3, 1.0)  
β (95% CI) (Adjusted model)b - -2.8 (-8.9, 3.3) -0.9 (-5.5, 3.7)  
Fine motor    0.77 
Mean (SD) 50.0 (11.1) 47.5 (11.6) 50.1 (11.1)  
β (95% CI) (Unadjusted model) - -2.5 (-8.3, 3.4) 0.1 (-3.8, 3.9)  
β (95% CI) (Adjusted model)b - -3.6 (-9.7, 2.6) -0.9 (-5.6, 3.9)  
Receptive Language    0.79 
Mean (SD) 45.6 (7.9) 45.9 (7.1) 46.2 (8.8)  
β (95% CI) (Unadjusted model) - 0.3 (-4.1, 4.6) 0.5 (-2.1, 3.2)  
β (95% CI) (Adjusted model)b - -0.8 (-5.4, 3.8) -0.9 (-4.2, 2.5)  
Expressive Language    0.44 
Mean (SD) 53.2 (9.0) 50.5 (8.7) 53.2 (8.3)  
β (95% CI) (Unadjusted model) - -2.7 (-7.5, 2.2) 0.0 (-3.0, 3.1)  
β (95% CI) (Adjusted model)b - -4.4 (-9.8, 0.9) -1.5 (-5.4, 2.4)  
Composite    0.64 
Mean (SD) 99.7 (13.6) 95.2 (12.8) 98.6 (13.7)  
β (95% CI) (Unadjusted model) - -4.5 (-11.8, 2.8) -1.2 (-5.7, 3.4)  
β (95% CI) (Adjusted model)b - -5.6 (-13.3, 2.0) -2.0 (-7.6, 3.7)  
aTrend tests are reported for the adjusted models 
bCovariates include preterm birth, maternal education, self-esteem, trait anxiety, postpartum perceived stress  
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Table 6.4. Results of linear regression models for the association between maternal perceived stress score in the fourth postpartum month 
and scores on the Mullen Scales of Early Learning: Pregnancy, Infection, and Nutrition (PIN), PIN Postpartum and PIN Babies Studies, 
2002-2006 
 Cohen’s Perceived Stress Scale score  
 Score=0-<11 
(n=120, 33.5%) 
11-<17 
(n=150, 41.9%) 
17+ 
(n=88, 24.6%) 
P for trenda 
Mullen Scales of Early Learning     
Gross motor    0.19 
Mean (SD) 49.6 (13.7) 49.0 (10.6) 51.8 (11.6)  
β (95% CI) (Unadjusted model) - -0.6 (-3.5, 2.3) 2.2 (-1.1, 5.5)  
β (95% CI) (Adjusted model)b - -0.9 (-3.9, 2.1) 3.0 (-0.8, 6.7)  
Visual reception    0.77 
Mean (SD) 50.4 (11.2) 49.9 (11.6) 47.6 (9.6)  
β (95% CI) (Unadjusted model) - -0.5 (-3.2, 2.1) -2.8 (-5.9, 0.3)  
β (95% CI) (Adjusted model)b - 0.5 (-2.3, 3.2) -0.8 (-4.2, 2.6)  
Fine motor    0.13 
Mean (SD) 49.5 (11.5) 49.8 (11.1) 50.6 (10.8)  
β (95% CI) (Unadjusted model) - 0.3 (-2.4, 3.0) 1.0 (-2.1, 4.1)  
β (95% CI) (Adjusted model)b - 1.2 (-1.6, 4.0) 2.4 (-1.0, 5.8)  
Receptive Language    0.05 
Mean (SD) 45.5 (7.5) 45.2 (8.4) 46.8 (7.8)  
β (95% CI) (Unadjusted model) - -0.3 (-2.2, 1.6) 1.3 (-0.9, 3.5)  
β (95% CI) (Adjusted model)b - 0.2 (-1.8, 2.2) 2.8 (0.3, 5.3)  
Expressive Language    0.06 
Mean (SD) 52.4 (9.7) 52.9 (8.8) 54.3 (8.1)  
β (95% CI) (Unadjusted model) - 0.4 (-1.7, 2.6) 1.9 (-0.6, 4.3)  
β (95% CI) (Adjusted model)b - 1.0 (-1.3, 3.2) 2.8 (-0.1, 5.6)  
Composite    0.09 
Mean (SD) 99.4 (14.1) 99.3 (13.8) 99.8 (12.7)  
β (95% CI) (Unadjusted model) - -0.1 (-3.4, 3.2) 0.4 (-3.4, 4.2)  
β (95% CI) (Adjusted model)b - 1.3 (-2.1, 4.6) 3.3 (-0.9, 7.4)  
aTrend tests are reported for the adjusted models 
bCovariates include preterm birth, maternal education, self-esteem, trait anxiety 
  
 
CHAPTER 7 
RESULTS 
Specific Aim 3: Perinatal depressive symptoms and the concentration of 
docosahexaenoic acid in breast milk 
 
Introduction 
Pregnancy and new motherhood are particularly stressful periods for many women, 
with depression during pregnancy affecting an estimated 12 to 18% of women and 
postpartum depression affecting up to 19% of new mothers.23, 24  Several studies have shown 
that depressed women tend to have impaired interaction with their infant, and negative 
effects on child development have been observed into the school-age years.26, 27, 29-31 
Low levels of long-chain polyunsaturated fatty acids (LCPUFAs), particularly 
docosahexaenoic acid (DHA), have been noted in the red blood cell and plasma cell 
membranes and brain orbitofrontal cortex tissue of clinically depressed adults.43, 44, 195  
Pregnancy may exacerbate low DHA status because maternal stores of DHA are mobilized to 
support the rapid development of the fetal brain.49  A handful of studies have noted lower 
postpartum plasma DHA levels among women with postpartum depression, but the results 
have been inconsistent and none have examined DHA levels in the breast milk.196, 204-206  A 
few clinical trials have evaluated whether n-3 fatty acid supplements might prevent perinatal 
depression or reduce symptoms, with mostly negative findings.207-211 
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In the postpartum period, maternal DHA stores are a major source of DHA for the 
infant via breast milk.  Approximately 73% of U.S. infants are breastfed for at least some  
time, and 12% are exclusively breastfed for the first 6 months.203  Some studies have 
observed a positive association between infant DHA intake and developmental outcomes 
such as visual acuity, although studies have often been conflicting.116, 239, 256, 257   
If women with elevated perinatal depressive symptoms also have reduced DHA 
content of their breast milk, then it would appear that perinatal depression could have 
both psychosocial and nutritional influences on infant development.  The aim of the 
current study was to examine whether women with depressive symptoms at various time 
points during pregnancy and postpartum have lower breast milk DHA content. 
 
Methods 
Study population 
Data were collected as part of the Pregnancy, Infection, and Nutrition Study 
(PIN) and its postnatal follow-up component, PIN Postpartum.  The goal of the PIN 
Study was to identify factors associated with preterm birth.  The goal of PIN 
Postpartum was to identify modifiable behaviors associated with high gestational 
weight gain and postpartum weight retention.45 All protocols were approved by the 
University of North Carolina (UNC) Biomedical Institutional Review Board; all 
participants provided written informed consent.   
 Women (n=1,169) were eligible for PIN Postpartum if they completed the 
third wave of the PIN Study, agreed to be contacted after delivery and lived in the 
study area.  Medical constraints (n=24), inability to recontact (n=207) or schedule 
 106 
(n=62), and refusal (n=187) resulted in 689 women who participated in a visit 
scheduled in the fourth postpartum month.  Women were eligible to provide a breast 
milk sample if they delivered their child between February 2004 and May 2007 
(n=519) and were still breastfeeding and living in the area, but 165 women never 
initiated or had discontinued breastfeeding by the time of the visit.  Some women 
were unable (n=26) or declined (n=23) to provide a sample; 305 provided a sample 
(304 were analyzable). 
 
Breast milk collection and fatty acid analysis 
Women were asked to use a breast pump at around 10 AM on the day of the 
postpartum visit to provide three 1.5 ml tubes of milk for storage at -80 degrees 
Celsius at the study office.  Samples were analyzed for fatty acid content by two 
laboratories.  Samples collected before April 1, 2005 were analyzed by the 
Collaborative Studies Clinical Laboratory at the University of Minnesota Medical 
Center, Fairview (Minneapolis, Minnesota).  This lab was unable to complete the 
analysis for the second batch of samples, so those collected after April 1, 2005 were 
analyzed by the Clinical Nutrition Research Center, UNC (Chapel Hill, North 
Carolina).  Fatty acid extraction was performed on 0.5 ml samples of breast milk 
mixed with 0.5 ml 0.9% saline using the method of Bligh and Dyer.241  The 
chloroform phase was transferred to a clean tube and evaporated to dryness under a 
nitrogen flow.  Residual lipids were saponified and fatty acids were transmethylated 
by sequentially adding 1ml 4.25% NaOH in CHCl3:MeOH (2:1, v/v) and 1N HCl in 
saline.242  After vigorous mixing, the samples were centrifuged at 1500g for 5 
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minutes.  The fatty acid methyl esters in the lower phase were evaporated to dryness 
under nitrogen and then resuspended in 50 µl undecane and analyzed by capillary gas 
chromatography (injector 240°, detector 280°).  To check the efficacy of the 
extraction, 0.1 mg 17:0 standard (diheptadecanoyl phosphatidylcholine) was added.  
The individual fatty acids were identified by comparison with authentic standards (Nu 
Chek Prep, Elysian, MN).  Data were analyzed using Perkin Elmer Totalchrom 
Chromatography Software, version 6.2 (Somerset, NJ). 
 
Depressive symptoms 
During pregnancy, information about depressive symptoms was collected via 
self-administered questionnaires before 20 weeks gestation and at 24-29 weeks 
gestation using the Centers for Epidemiologic Studies Depression (CES-D) scale.212  
The CES-D is intended to measure depressive symptoms in general population 
samples.  Women who scored above 16 on the CES-D were classified as having 
minor or major depressive symptoms.  The 16/17 cutpoint for the CES-D was chosen 
because several studies have reported reduced specificity of the CES-D using the 
15/16 cutpoint for pregnant women because some symptoms of pregnancy (e.g., 
fatigue) are similar to CES-D components.225-227  
 In the fourth postpartum month, women were interviewed in the home and 
screened for depressive symptoms using the Edinburgh Postnatal Depression Scale 
(EPDS).215  Women who scored above 9 on the EPDS were classified as having 
minor or major depressive symptoms.  The 9/10 cutpoint for the EPDS has been 
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validated in previous studies and has been shown to increase the sensitivity of the 
instrument to minor depression.228-230 
 
Covariate measurement 
Age, education, and other demographic and lifestyle covariates were obtained 
via telephone at 17-22 weeks gestation.  At the clinic visit at 24-29 weeks gestation, 
women were asked to complete a modified version of the Block Food Frequency 
Questionnaire (FFQ) to assess diet during the previous three months, from which 
estimated daily dietary intake of n-3 fatty acids for the three previous months was 
calculated.258, 259  At the postpartum visit, information was collected about current 
smoking and the presence of a spouse or partner in the woman’s life. 
 
Statistical analysis 
 We used t-tests and one-way analysis of variance to examine the difference in 
mean breast milk DHA concentration between groups with elevated depressive symptoms 
(i.e., above the cutpoint for the particular depressive symptoms screener) versus few 
depressive symptoms (i.e., below the cutpoint for the screener) at each time point 
depressive symptoms were measured.  To consider whether the DHA status of women 
who scored above the cutpoint multiple times differed from the DHA status of women 
who scored above the cutpoint zero or one times, we formed a variable for the count of 
the number of times women scored above a cutpoint.  DHA concentration was 
approximately log-normally distributed, so it was log-transformed for use in regression 
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models.  The association between depressive symptoms and logDHA was examined 
using linear regression.   
Potential covariates were identified a priori based on previous studies and 
constructed Directed Acyclic Graphs.234, 235  Multiple partial F-tests checked for the 
presence of effect measure modification.  Covariates included in the regression models 
included maternal age (tertiles), education (0-12, 13-16, >16 years), estimated daily 
intake of n-3 fatty acids (quartiles), presence of a spouse or partner (yes/no), smoking 
(ever during pregnancy or postpartum versus none), and a variable for laboratory. 
 
Results 
 All women except participated in at least one assessment of depressive symptoms, 
leaving 303 total women eligible for inclusion in this analysis.  The proportion of women 
scoring above the cutpoint on the first or second prenatal CES-D or the postpartum EPDS 
was 11.9%, 15.8%, and 11.2%, respectively; and 8.6% scored above the relevant cutpoint 
at 2 or 3 of the time points these instruments were administered (Table 7.1).  Elevated 
depressive symptoms were associated with fewer years of maternal education, absence of 
a spouse or partner, smoking, and younger maternal age; these associations were 
strongest among women who scored above the cutpoint 2-3 times. 
The mean breast milk DHA concentration was 0.28% (SD=0.22) and ranged 
0.07%-1.49%.  Women with more years of education had higher breast milk DHA levels 
on average than women with less education.  Mean DHA concentration also differed by 
laboratory (t=-7.2, p<0.01).  DHA levels were 25% lower among women with elevated 
depressive symptoms at less than 20 weeks gestation compared to women with few 
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depressive symptoms at that time (adjusted β for logDHA= -0.22, 95% CI: -0.42, -0.03) 
(Table 7.2).  There was a suggestion of a similar association with the number of times 
women scored above a depressive symptoms screener cutpoint.  DHA levels were 19% 
lower for women who scored above a cutpoint 2-3 times compared to women who never 
scored above a cutpoint, although this estimate was imprecise (adjusted β for  
logDHA=-0.17, 95% CI: -0.40, 0.06).  All women with elevated depressive symptoms at 
less than 20 weeks gestation had DHA levels below 0.45%, and all women with elevated 
symptoms at 2-3 time points had DHA levels below 0.35%.  Women with elevated 
depressive symptoms at 24-29 weeks gestation or postpartum did not have lower breast 
milk DHA levels than women with few depressive symptoms at those time points.  We 
re-examined models with dietary n-3 intake excluded and observed no difference in the 
results. 
 
Discussion 
 The goal of this study was to examine whether women who experienced elevated 
depressive symptoms during pregnancy or postpartum also had lower DHA levels in their 
breast milk.  A few previous studies have noted lower DHA levels as measured in 
plasma, but DHA levels in breast milk are a better reflection of infant dietary 
exposure.196, 204, 206  Our interest lies in infant dietary exposure since infant exposure to 
LCPUFAs is a prominent component of this dissertation.  
Depressive symptoms early in pregnancy could reflect maternal affect over a long 
period of time pre-conception through early pregnancy.  Likewise, breast milk DHA 
levels are more reflective of long-term stores of fatty acids and lifetime diet than short 
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term influences.260  If women who are chronically depressed have low DHA stores, then 
it might be reflected in the breast milk.  In contrast, depression later in pregnancy or 
postpartum might be related to perinatal events, and women who have a brief depressive 
episode might not exhibit lower DHA levels in breast milk. 
 While there has been growing interest in the relation between depression and 
DHA, studies have been unable to verify the temporal direction of the association.  It is 
possible that depressed individuals have lower dietary n-3 intake, but this appears to be 
an incomplete explanation as some studies have observed no association between dietary 
intake and depressive symptoms and the results of trials to evaluate DHA supplements to 
treat depression have often been negative.206, 211, 261-263  Other indications are that 
depressed individuals may have impaired DHA synthesis or accelerated breakdown of 
DHA.197  This study cannot verify the temporal direction; however, our intention was not 
to uncover the mechanisms involved but to understand the relationship between 
depressive symptoms and DHA status in the context of fatty acids in the diets of 
breastfed infants.   
Few studies in this area have focused on maternal affect in the perinatal period 
(most are unrelated to pregnancy).  Of the perinatal studies, one observed no relationship 
between postpartum depression and DHA status, while three others observed that 
decreasing DHA levels were accompanied by increasing depressive symptoms, based on 
plasma DHA levels.196, 204-206 
The proportion of women who experienced significant depressive symptoms in 
this study is similar to other studies, and the mean DHA concentration in the breast milk 
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samples in this study was in the range of other U.S. studies.  For instance, Birch et al. 
found mean DHA levels of 0.29%.63   
 Some weaknesses of our study deserve mention.  First, a clinical diagnosis of 
depression might be preferred over the use of depressive symptoms screeners; however, 
if an effect is observed at sub-clinical levels of depressive symptoms, it indicates a larger 
proportion of individuals might be affected, not only those who are clinically depressed.  
Second, we cannot rule out reduced dietary intake of n-3 fatty acids among individuals 
with elevated depressive symptoms as the reason for low DHA levels.  However, we 
included n-3 intake in our regression models, and our results did not change when it was 
removed from the models.  Several issues limit our ability to extend this analysis further 
at this time.  For instance, incorporating information about red blood cell DHA 
concentrations during pregnancy would provide more information about antepartum 
DHA status, and red blood cell levels are a better indicator of maternal DHA status.  
Also, the PIN Babies Study has too few infants to examine the interaction between 
maternal perinatal depressive symptoms and infant exposure to LCPUFAs, so we cannot 
examine whether infants who are exposed to both maternal psychological distress and 
low levels of LCPUFAs demonstrate poorer developmental outcomes than infants 
exposed to only one or none of these. 
One strength of this study is that it included three depressive symptoms 
assessments instead of just one, and two of the three assessments occurred during 
pregnancy which no previous studies have included.  Second, we chose to measure DHA 
in breast milk, which may be a better marker of infant DHA exposure than DHA 
measured in plasma and red blood cells even though plasma and red blood cells may be 
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better markers of maternal DHA status.  Third, most previous studies of perinatal 
depression and DHA status involved patients with clinical depression.  We were able to 
examine associations in a sample of women unselected for pre-existing mental health 
conditions who experienced from very few to many depressive symptoms. 
 
Conclusion 
 Women who experienced elevated depressive symptom early in pregnancy had 
25% less DHA in their breast milk than women who experienced few symptoms.  This 
difference may or may not be meaningful in terms of infant DHA exposure.  The 
difference in DHA content of the treatment versus control formulas in infant feeding 
trials is greater than this, and the results of these trials (usually focused on 
neurodevelopment) are mixed.  It is possible that any benefits might be more apparent at 
high doses.116, 239, 256, 257  Regardless, perinatal depression remains an exposure of concern 
for clinicians and families due to its psychosocial influence on child development.  A 
possible negative effect on infant nutrition is another reason to seek ways to reduce the 
prevalence of perinatal depression.  If DHA supplementation can prevent or lessen 
depressive symptoms, it could have the added benefit of increasing the amount of DHA 
available to infants, if DHA indeed benefits child development. 
  
114
 
Table 7.1.  Characteristics of Women in the PIN Postpartum Study and Associations with Depressive Symptoms and Breast Milk DHA Concentration, 
2002-2006 
 CES-D, <20 weeks gestation 
(n, %) 
CES-D, 24-29 weeks gestation (n, %) EPDS, 4th month 
postpartum (n, %) 
Mean DHA 
concentration of breast 
milk (% of total fatty 
acids) (SD) 
 0-16 17+ missing 0-16 17+ missing 0-9 10+  
Overall 253 (83.5) 36 (11.9) 14 (4.6) 225 (74.3) 48 (15.8) 30 (9.9) 269 (88.8) 34 (11.2) 0.28 (0.22) 
Maternal education          
0-12 years 11 (64.7) 4 (23.5) 2 (11.8) 8 (47.1) 7 (41.2) 2 (11.8) 13 (76.5) 4 (23.5) 0.31 (0.24) 
13-16 112 (78.3) 24 (16.8) 7 (4.9) 103 (72.0) 25 (17.5) 15 (10.5) 124 (86.7) 19 (13.3) 0.25 (0.19) 
>16 130 (90.9) 8 (5.6) 5 (3.5) 114 (79.7) 16 (11.2) 13 (9.1) 132 (92.3) 11 (7.7) 0.17 (0.09) 
Smoking          
Yes 9 (56.3) 7 (43.8) 0 8 (50.0) 7 (43.8) 1 (6.3) 12 (75.0) 4 (25.0) 0.30 (0.24) 
No 244 (85.0) 29 (10.1) 14 (4.9) 217 (75.6) 41 (14.3) 29 (10.1) 257 (89.6) 30 (10.5) 0.28 (0.22) 
Maternal age (years) 
         
17-20 3 (50.0) 3 (50.0) 0 2 (33.3) 3 (50.0) 1 (16.7) 5 (83.3) 1 (16.7) 0.16 (0.05) 
21-30 113 (79.0) 20 (14.0) 10 (7.0) 101 (70.6) 27 (18.9) 15 (10.5) 124 (86.7) 19 (13.3) 0.28 (0.23) 
31-47 137 (89.0) 13 (8.4) 4 (2.6) 122 (79.2) 18 (11.7) 14 (9.1) 140 (90.9) 14 (9.1) 0.28 (0.21) 
Daily dietary n-3 
intake 
         
>=75th percentile 55 (80.9) 11 (16.2) 2 (2.9) 53 (77.9) 12 (17.7) 3 (4.4) 61 (89.7) 7 (10.3) 0.32 (0.29) 
50-<75th percentile 63 (91.3) 6 (8.7) 0 57 (82.6) 12 (17.4) 0 65 (94.2) 4 (5.8) 0.24 (0.13) 
25-<50th percentile 56 (87.5) 6 (9.4) 2 (3.1) 52 (81.3) 10 (15.6) 2 (3.1) 56 (87.5) 8 (12.5) 0.28 (0.25) 
0-<25th percentile 64 (83.1) 11 (14.3) 2 (2.6) 60 (77.9) 14 (18.2) 3 (3.9) 69 (89.6) 8 (10.4) 0.28 (0.19) 
missing 15 (60.0) 2 (8.0) 8 (32.0) 3 (12.0) 0 22 (88.0) 18 (72.0) 7 (28.0) 0.24 (0.12) 
Presence of spouse or 
partner 
         
Yes 250 (84.8) 32 (10.9) 13 (4.4) 222 (75.3) 46 (15.6) 27 (9.2) 264 (89.5) 31 (10.5) 0.28 (0.22) 
No 3 (37.5) 4 (50.0) 1 (12.5) 3 (37.5) 2 (25.0) 3 (37.5) 5 (62.5) 3 (37.5) 0.24 (0.11) 
Laboratory          
Minnesota 149 (85.1) 19 (10.9) 7 (4.0) 132 (75.4) 27 (15.4) 16 (9.1) 153 (87.4) 22 (12.6) 0.20 (0.14) 
North Carolina 104 (81.3) 17 (13.3) 7 (5.5) 93 (72.7) 21 (16.4) 14 (10.9) 116 (90.6) 12 (9.4) 0.38 (0.26) 
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Table 7.2.  Breast milk fatty acid concentration (logDHA) by depressive symptoms categories: Pregnancy, Infection, and Nutrition (PIN) and PIN 
Postpartum studies, 2002-2006 
LogDHA CES-D (<20 weeks 
gestation) (0-16=ref) 
CES-D (24-29 weeks 
gestation) (0-16=ref) 
EPDS (4th month 
postpartum) (0-9=ref) 
Number of times scored above a depressive 
symptoms screener cutpointa (0=ref) 
 
 
17+ 17+ 10+ 1 2-3 
β (95% CI) 
Unadjusted model 
-0.20 (-0.42, 0.02) -0.07 (-0.26, 0.12) 
 
-0.11 (-0.33, 0.12) 0.03 (-0.17, 0.23) -0.23 (-0.48, 0.02) 
β (95% CI) 
Adjusted modelb 
-0.22 (-0.42, -0.03) -0.05 (-0.22, 0.12) -0.02 (-0.21, 0.17) 0.00 (-0.17, 0.18) -0.17 (-0.40, 0.06) 
a Count of the number of times scored above 16 on the CES-D or above 9 on the EPDS 
bAdjusted models included: maternal age, estimate of daily dietary n-3 intake during pregnancy, education, smoking, presence of a spouse or partner, and 
laboratory 
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Figure 7.1. Distribution of Breast Milk DHA by Depressive Symptoms Categories 
 
 
  
CHAPTER 8 
CONCLUSIONS 
Overview 
The goal of the present study was to fill gaps in the understanding of the roles of 
LCPUFA intake and maternal perinatal depression in infant neurodevelopment.  Impaired 
development early in life can translate into lifelong cognitive deficits and behavioral 
disorders.  Improved understanding of the role of LCPUFA intake in cognitive development 
can help optimize early life nutrition for development.  Additionally, refined understanding 
of the role of perinatal depression, particularly when considered in relation to infant nutrition 
and other psychosocial influences, can potentially help direct mental health services or 
nutritional interventions.   
This study built on an existing large pregnancy cohort study with an infant follow-up 
component and, thus, had a large database of prospective psychosocial, nutritional, and 
developmental data from which to draw.  We developed a Conceptual Model that integrated 
the exposures and outcomes under study within the context of the perinatal period and 
infancy. 
The results of our analysis suggest that differences in visual reception, language, and 
motor skills, and overall cognitive development among infants at 12 months may be 
explained by factors other than DHA and AA exposure, breastfeeding duration and 
exclusivity, and the socio-demographic factors that underlie choices about feeding method.  
We also examined the role of maternal psychological health in cognitive development and 
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found that maternal trait anxiety, but not perinatal depressive symptoms or perceived stress, 
was associated with reduced receptive language ability and overall cognition, but the 
differences were small.  However, women who experienced elevated depressive symptoms 
early in pregnancy or at several points during the perinatal period had lower levels of DHA 
available to their infants via their breast milk.  It is possible that the effects of LCPUFA 
exposure and maternal psychological health become more apparent after infancy or that our 
sample size limited the ability to detect small differences.   
 
 
Strengths and limitations 
LCPUFA exposure measurement 
Despite the large number of studies that have examined the association between the 
LCPUFA content of infant formulas and various neurodevelopmental outcomes, there is no 
consensus about whether LCPUFAs enhance development.  One reason for this may be the 
variety of exposure measures used in these studies and their ability to reflect infants’ 
complex feeding patterns.  Most studies do not take into account the wide variation in the 
extent to which infants are breastfed or formula fed and the differences in LCPUFA content 
of breast milk.  Infant feeding trials generally use intent-to-treat analysis which can limit the 
generalizability of findings.  This study had the benefit of detailed information about 
breastfeeding and formula use over time, and we used this information to develop a novel 
exposure measure that combined both sources.  It was clear that feeding practices changed 
fairly frequently in this cohort: shifts in the number of feedings that were breastfed to 
formula fed and changes in the formula products used over time.  Our exposure measurement 
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approach was able to capture this complexity and so is more reflective of actual infant 
feeding patterns compared to the intent-to-treat driven approaches used in infant feeding 
trials.  Also, we were able to include some infants fed formulas with no DHA or AA added.  
This increased the variability of exposure compared to what might be observed in a sample 
of infants born more recently because almost all formula products today contain DHA and 
AA.  In fact, a cohort of infants enrolled just a couple of years after this one might have zero 
infants fed only formulas without DHA and AA, making it impossible to have an unexposed 
comparison group.   
Despite these strengths, this study was subject to some limitations pertaining to the 
ability to measure infant exposure to LCPUFAs.  First, we had very few infants fed only 
formulas without supplemental DHA and AA for all months to allow direct comparison with 
infants fed only formulas with DHA and AA.  This is because formulas with DHA and AA 
have increasingly displaced formulas without DHA and AA.  Also, the formulas tend to have 
similar amounts of DHA and AA added, and this somewhat limits the variability in exposure.  
Second, despite the detailed nature of our novel exposure measure, it cannot capture some of 
the inter-individual and intra-individual variability in LCPUFA exposure across time.  For 
instance, the study relied on a single breast milk measurement as the basis for estimating 
LCPUFA exposure from breast milk, thereby not capturing any possible variability in 
LCPUFA content of breast milk across lactation.  Also, the study did not have information 
available on the amount of formula or breast milk consumed per feeding (or how this 
changed over time) so some variability in LCPUFA exposure was not accounted for.  In 
addition, because some women stopped breastfeeding before the study visit or refused to 
provide a breast milk sample, we were unable to directly measure their infants’ exposure via 
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breast milk.  Finally, two depression symptoms instruments were used in this study; 
consistent use of a single instrument might have been preferred.  Because of these 
limitations, the results of this study should be interpreted with caution.  It is possible that this 
study underestimated the potential benefits of breastfeeding or LCPUFA exposure on infant 
development, particularly in light of the null results for the breastfeeding models which one 
might have expected to suggest a benefit.  The null results for LCPUFA exposure are less 
surprising given that the majority of studies in this area have shown no benefit to cognitive 
development. 
 
Outcome measurement – infant development 
Assessing infant development is difficult and somewhat subjective because infant 
behavior in testing situations is variable and to some degree relies on input from mothers, 
who may vary in their ability to provide objective information.  Assessments of young 
children are sensitive to rapport with the examiner as well.  In addition, developmental 
assessments of infants tend to have somewhat limited predictive value largely because of the 
rapid developmental changes occurring in infancy.  Few studies of LCPUFA exposure assess 
infant development beyond a measure of global development, like the Bayley.  A major 
strength of this study was the use of the Mullen which simultaneously assesses multiple 
domains of infant development using five sub-scales and an overall composite.  As a result, 
this study was able to assess whether the exposures varied in their associations by domain. 
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Study design and study population 
Several features of the PIN Study design served as strengths and limitations to the 
analyses presented here.  First, the prospective design of this study was a strength in that it 
avoided assessing the exposures based on recall or confusing the temporal sequence of the 
exposures and outcomes.  The length of the follow-up period allowed for study of exposures 
during pregnancy with developmental outcomes more than one year later.  Some previous 
studies were not able to study prenatal exposures or to follow infants for as many months.  
Second, while the women were recruited into this observational study via prenatal care 
clinics, they were not selected based on any pre-existing condition or screened for mental 
health characteristics.  Also, infants were breastfed or formula fed according to what the 
family chose, not assigned to one particular method or product.  These are strengths in that 
this study population might resemble the general population of women and infants more 
closely than a sample selected for prior depression history, for instance.  Consequently, the 
results of this study might be more applicable to the general population than the clinical trials 
in this area.  However, because the exposure prevalence (e.g., for maternal perinatal 
depressive symptoms) was fairly low in this sample and the sample was limited in size, we 
might have been unable to detect small differences between groups in this study that might 
have been apparent in a larger sample.  This might explain some of our null results.  Also 
because of our limited sample size we were unable to examine the effect of changes in 
depressive symptoms across pregnancy and the postpartum period.  Third, with any 
prospective cohort study, selection bias is a limitation.  The infants who participated in the 
developmental assessments at 12 months of age were a select group—those whose mothers 
completed the PIN Study and elected to continue into the PIN Postpartum component to 12 
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months.  Women who experienced significant depressive symptoms or anxiety during 
pregnancy or high perceived stress postpartum were somewhat less likely to participate 
postpartum.  If these children would also have scored lower on the Mullen scales than 
participating children, our results may underestimate the true association, but the data to 
evaluate this were unavailable.  Finally, a prospective cohort study is normally considered a 
weaker design than a randomized controlled trial due to the trial’s ability to handle 
confounding factors by randomization.  However, when infant feeding trials include a non-
randomized breastfed comparison group, this advantage no longer applies to comparisons 
involving this group, especially if key confounders are not addressed in the analysis.  As 
such, the observational design of the present study is not necessarily a disadvantage, 
especially since we were able to incorporate key confounders into our analyses pertaining to 
feeding method. 
 
Implications 
 Our findings suggest that maternal trait anxiety interferes to a slight extent with 
optimal infant cognitive development, and this is apparent by 12 months of age.  Because 
trait anxiety is a stable characteristic of the individual, it is not easily modifiable but 
techniques for stress management and reliance on supportive family and friends might help 
buffer the potential effects of anxiety.  Pharmaceutical interventions to control anxiety may 
be unwise during pregnancy and lactation.  Our findings about depressive symptoms and 
breast milk DHA status support existing proposals that improving DHA status during 
pregnancy might help relieve depressive symptoms.  Since DHA is naturally available in 
certain foods like fatty fish and also in over-the-counter supplements, recommendations for 
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pregnant women at risk of depression to consume more DHA could be implemented.  To 
date, clinical trials in this area have failed to show relief from postpartum depression from 
DHA supplementation, but there have only been a few small studies.  Also, there is 
uncertainty about the effects of large doses of DHA and concern about exposure to high 
levels of mercury and polychlorinated biphenyls in seafood.  Whether consuming more DHA 
can help manage anxiety as well remains to be seen, but at least one study suggests it is a 
possibility.264  Aside from its potential to reduce depressive symptoms in adults, the benefits 
of DHA to infant development remain uncertain as well.  Our results indicated no benefit 
from LCPUFA intake, whether from breast milk or formula.  Many previous feeding trials 
have shown similar results, and results overall have been equivocal.17, 103, 110, 114  Most 
clinical trials that randomized women to LCPUFA supplements to examine effects on infant 
development have been unable to show any benefit to development from this method of 
supplementation.143-148  As a result, if it is found that maternal supplementation helps with 
depressive symptoms, it cannot be expected that maternal supplementation will benefit infant 
development simultaneously.  Given the conflicting results among previous studies and the 
strengths and limitations of this study, no actions are warranted to change infant feeding 
practices at this time except to provide a note of caution that the effects of LCPUFA 
supplementation of infants remain unclear and deserve further study. 
 
Directions for Future Research 
 Future studies in five key areas are recommended to advance this field of research.  
First, studies of infant development should follow children longer into the school age years 
and examine specific developmental domains in relation to early life exposures to maternal 
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psychosocial influences, LCPUFAs, and the interaction between them.  Second, larger 
studies should be designed to better pinpoint the optimal intake of n-3 fatty acids for women 
and LCPUFAs for infants.  Feeding or supplementation dose-ranging trials covering a wider 
range of doses would be useful.  The increasing acceptance and ubiquity of formula products 
and baby foods with LCPUFAs added might make forming an unexposed comparison group 
of infants for these studies more difficult, however.  Third, methods development studies 
should be conducted to develop better ways of assessing infant exposure to LCPUFAs in 
ways that are applicable to the general population of infants and their complex feeding 
patterns.  Fourth, more basic research into the neurophysiologic mechanisms involved in the 
relationship between n-3 fatty acids and mental health would help clarify the direction of the 
association between them and better direct efforts to improve mental health and optimize n-3 
fatty acid status.  Finally, because infant cognition is a product of complex interactions 
between multiple influences, future studies of infant development in this area should avoid 
examining one exposure alone and instead focus on the interactions between genetics (e.g., 
fatty acid desaturase genes), diet, and the psychosocial environment. 
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APPENDIX 1. 
 
DHA and AA Content of Common Infant Formulas in Powder Form, 2002-2006a 
Manufacturer Formula Product DHA (g/100g 
edible portion) 
AA (g/100g edible 
portion) 
Mead Johnson Enfamil AR LIPIL 0.087 0.164 
 Enfamil EnfaCare 0 0 
 Enfamil EnfaCare LIPIL 0.080 0.170 
 Enfamil Lactose Free 0 0 
 Enfamil Lactose Free 
LIPIL 
0.090 0.180 
 Enfamil LIPIL 0.090 0.175 
 Enfamil LIPIL with iron 0.089 0.168 
 Enfamil low iron 0 0 
 Enfamil with iron 0 0 
 Nutramigen 0 0 
 Nutramigen LIPIL 0.080 0.170 
 ProSobee 0 0 
 ProSobee LIPIL 0.085 0.170 
Ross Alimentum 0 0 
 Alimentum Advance 0.011 0.018 
 Isomil 0 0 
 Isomil Advance 0.096 0.187 
 Neosure 0 0 
 Similac Advance 0.096 0.187 
 Similac Lactose Free 0 0 
 Similac low iron 0 0 
 Similac with iron 0 0 
Carnation Good Start 0 0 
 Good Start with iron, 
DHA, ARA 
0.084 0.167 
Other Kirkland DHA, iron 0.103 0.181 
a
 Source: U.S. Department of Agriculture Nutrient Database for Standard Reference221 
(except for Carnation products, source: Nestle Infant Nutrition Center website222).
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APPENDIX 2 
 
Participants for the present study from PIN, PIN Postpartum, PIN Babies Studies 
 
3203  invited to participate in PIN3 
2006 agreed to participate in PIN3 
375 Became Ineligible/Dropped out of PIN3: 
    33 lost pregnancy 
    87 requested to drop out 
    84 did not complete PIN Phone Interview 1 
      4 multiple births 
    42 did not deliver at UNC Hospitals 
    72 requested no future contact 
    45 moved out of area/lost contact 
      8 medical problems at delivery 
1169 eligible for PIN Postpartum 
689 agreed to participate, attended 3-mo visit 
(305 provided breast milk) 
1197 declined 
      0 otherwise excluded 
281 Ineligible/Dropped out of Study: 
    45 became pregnant 
    62 unreachable 
    29 moved out of area 
    20 requested to leave study 
  125 infants reached 12 months before assessments 408 attended 12-mo visit  
(358 completed at least partial Mullen. 21 
child asleep, sick, fussy; 11 infant not 
present; 8 refused; 3 not enough time; 7 other 
reasons) 
462 delivered before Postpartum Study recruitment 
480 Ineligible or Refused: 
    24 medical constraints 
  207 unreachable 
  187 refused 
    62 unable to schedule 
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